<SEC-DOCUMENT>0001193125-14-071976.txt : 20140227
<SEC-HEADER>0001193125-14-071976.hdr.sgml : 20140227
<ACCEPTANCE-DATETIME>20140227123101
ACCESSION NUMBER:		0001193125-14-071976
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20140227
FILED AS OF DATE:		20140227
DATE AS OF CHANGE:		20140227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		14647609

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d684266d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of Foreign Private Issuer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of&nbsp;February 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 000-31062 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Oncolytics
Biotech Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite&nbsp;210, 1167 Kensington Crescent NW </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calgary, Alberta, Canada T2N 1X7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form&nbsp;20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a Form&nbsp;6-K
if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in
paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note:
</B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a Form&nbsp;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form&nbsp;6-K submission or
other Commission filing on EDGAR. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCORPORATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibits 99.1 and 99.2 included with this report on Form 6-K are expressly incorporated by reference into this report and are hereby incorporated by reference
as exhibits to the Registration Statement on Form F-10 of Oncolytics Biotech Inc. (File No.&nbsp;333-182260), as amended or supplemented. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS FILED </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the Exhibit Index
hereto. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Oncolytics Biotech Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:&nbsp;February 27, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">/s/&nbsp;Kirk Look</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Kirk Look</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:35.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:55.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Purchase Agreement with Lincoln Park Capital Fund, LLC dated February 27, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Placement Agent Agreement with Bayridge Securities, LLC dated February 27, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">News Release dated February 27, 2014</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d684266dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>E<SMALL>XECUTION</SMALL> V<SMALL>ERSION</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>PURCHASE AGREEMENT</B> (the &#147;<U>Agreement</U>&#148;), dated as of February&nbsp;27, 2014, by and between <B>ONCOLYTICS BIOTECH
INC.</B>, a company incorporated under the <I>Business Corporations Act (Alberta)</I> (the &#147;<U>Company</U>&#148;), and <B>LINCOLN PARK CAPITAL FUND, LLC</B>, an Illinois limited liability company (the &#147;<U>Investor</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WHEREAS: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the
terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, in the Company&#146;s sole and absolute discretion, and the Investor wishes to buy from the Company, up to US$26,000,000 of the Company&#146;s common
shares, no par value (the &#147;<U>Common Shares</U>&#148;); <U>provided</U> that the market value of Common Shares distributed under any single Prospectus Supplement (as defined below) shall not exceed 10% of the aggregate market value of the
outstanding Common Shares as of the date specified in Section&nbsp;9.1 of National Instrument 44-102 <I>Shelf Distributions</I> (&#147;<U>NI 44-102</U>&#148;), which shall be calculated in accordance with Section&nbsp;9.2 of NI 44-102.
Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in the immediately preceding sentence on the number of Common Shares issued and sold under this Agreement and under any
single Prospectus Supplement shall be the sole responsibility of the Company, and the Investor shall have no obligation in connection with such compliance. The Common Shares to be purchased hereunder (including, without limitation, the Initial
Purchase Shares (as defined herein)) are referred to herein as the &#147;<U>Purchase Shares</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed
with the securities regulatory authorities (the &#147;<U>Canadian Qualifying Authorities</U>&#148;) in the provinces of British Columbia, Alberta, Manitoba and Ontario (the &#147;<U>Canadian Qualifying Jurisdictions</U>&#148;) a preliminary short
form base shelf prospectus dated June&nbsp;21, 2012, and a final short form base shelf prospectus dated July&nbsp;3, 2012, in respect of an aggregate of up to Cdn$150,000,000 in certain securities of the Company, including Common Shares
(collectively, the &#147;<U>Shelf Securities</U>&#148;), in each case in accordance with the applicable securities laws of each of the Canadian Qualifying Jurisdictions and the respective applicable rules and regulations under such laws, together
with applicable published national, multilateral and local policy statements, instruments, notices and blanket orders of the Canadian Qualifying Authorities in each of the Canadian Qualifying Jurisdictions (collectively, &#147;<U>Canadian Securities
Laws</U>&#148;). The Alberta Securities Commission (the &#147;<U>Reviewing Authority</U>&#148;) is the principal regulator of the Company under the passport system procedures provided for under Multilateral Instrument 11-102 <I>Passport System</I>
and National Policy 11-202 <I>Process for Prospectus Reviews in Multiple Jurisdictions</I> in respect of the offering of the Shelf Securities. The Reviewing Authority has issued a receipt evidencing that a receipt has been issued (a
&#147;<U>Receipt</U>&#148;) on behalf of itself and the other Canadian Qualifying Authorities in respect of such short-form base shelf prospectus (the final short-form base shelf prospectus dated July&nbsp;3, 2012 relating to the Shelf Securities,
as most recently amended, if applicable, filed with the Canadian Qualifying Authorities on or before the date of this Agreement for which a Receipt has been obtained, is hereinafter referred to as the &#147;<U>Canadian Base Prospectus</U>&#148;). As
used herein, &#147;<U>Canadian Prospectus Supplement</U>&#148; means the most recent prospectus supplement to the Canadian Base Prospectus relating to the Securities (as defined herein), to be filed by the Company with the Canadian Qualifying
Authorities in accordance with Canadian Securities Laws; and &#147;<U>Canadian Prospectuses</U>&#148; means the Canadian Prospectus Supplement (and any additional Canadian prospectus supplement prepared in accordance with the provisions of this
Agreement and filed with the Canadian Qualifying Authorities in accordance with Canadian Securities Laws) together with the Canadian Base Prospectus. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has also prepared and filed with the United States Securities and Exchange Commission
(the &#147;<U>SEC</U>&#148;<I>),</I> pursuant to the Canada/U.S. Multi-Jurisdictional Disclosure System adopted by the SEC (the &#147;<U>MJDS</U>&#148;), a registration statement on Form F-10 (File No.&nbsp;333-182260) registering the Shelf
Securities under the United States Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the &#147;<U>Securities Act</U>&#148;), and has filed such amendments to such registration statement on Form F-10, as
amended, as may have been permitted or required to the date of this Agreement. Such registration statement, including the Canadian Base Prospectus (with such deletions therefrom and additions thereto as are permitted or required by Form F-10 and the
Securities Act and including exhibits to such registration statement), has become effective in such form pursuant to Rule 467(b) under the Securities Act. Such registration statement, as amended when it last became effective under the Securities
Act, including all documents filed as a part thereof, the exhibits and any schedules thereto at such time and the documents incorporated by reference therein pursuant to Item&nbsp;4 of Form F-10 under the Securities Act at such time, is herein
called the &#147;<U>Registration Statement</U>.&#148; The Company has also filed with the SEC an appointment of agent for service of process on Form F-X (the &#147;<U>Form F-X</U>&#148;) in conjunction with the filing of the Registration Statement.
As used herein, &#147;<U>U.S. Base Prospectus</U>&#148; means the Canadian Base Prospectus, with such deletions therefrom and additions thereto as are permitted or required by Form F-10 and the Securities Act in the form in which it appeared in the
Registration Statement on the date it last became effective under the Securities Act; &#147;<U>U.S. Prospectus Supplement</U>&#148; means the Canadian Prospectus Supplement, with such deletions therefrom and additions thereto as are permitted or
required by Form F-10 and the Securities Act, to the U.S. Base Prospectus relating to the offering of the Securities, to be filed by the Company with the SEC pursuant to General Instruction II.L of Form F-10; &#147;<U>U.S. Prospectuses</U>&#148;
means the U.S. Prospectus Supplement (and any additional U.S. prospectus supplement prepared in accordance with the provisions of this Agreement and filed with the SEC in accordance with General Instruction II.L of Form F-10) together with the U.S.
Base Prospectus and together with any &#147;issuer free writing prospectus,&#148; as defined in Rule 433 under the Securities Act (&#147;<U>Rule 433</U>&#148;) relating to the Securities that (i)&nbsp;is required to be filed with the SEC by the
Company or (ii)&nbsp;is exempt from filing pursuant to Rule 433(d)(5)(i), in each case in the form filed or required to be filed with the SEC or, if not required to be filed, in the form retained in the Company&#146;s records pursuant to Rule
433(g). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As used herein, &#147;<U>Base Prospectuses</U>&#148; means, collectively, the Canadian Base Prospectus and the U.S. Base
Prospectus; &#147;<U>Prospectus Supplements</U>&#148; means, collectively, the Canadian Prospectus Supplement and the U.S. Prospectus Supplement; and &#147;<U>Prospectuses</U>&#148; means, collectively, the Canadian Prospectuses and the U.S.
Prospectuses. Any reference herein to the Registration Statement, the Base Prospectuses, the Prospectus Supplements or the Prospectuses or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by
reference therein, and any reference herein to the terms &#147;amend,&#148; &#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, the Base Prospectuses, the Prospectus Supplements or the Prospectuses shall be
deemed to refer to and include the filing or furnishing of any document with or to the SEC or Canadian Qualifying Authorities, as applicable, on or after the effective date of the Registration Statement or the date of the Base Prospectuses, the
Prospectus Supplements or the Prospectuses, as the case may be, and deemed to be incorporated by reference therein. For purposes of this Agreement, all references to the Canadian Base Prospectus, the Canadian Prospectus Supplement and the Canadian
Prospectuses or any amendment or supplement thereto shall be deemed to include any copy filed with any Canadian Qualifying Jurisdiction pursuant to the System for Electronic Document Analysis and Retrieval (&#147;<U>SEDAR</U>&#148;) and all
references to the Registration Statement, the U.S. Base Prospectus, the U.S. Prospectus Supplement and the U.S. Prospectuses or any amendment or supplement thereto shall be deemed to include any copy filed with the SEC pursuant to the Electronic
Data Gathering Analysis and Retrieval System (&#147;<U>EDGAR</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CERTAIN DEFINITIONS. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, the following terms shall have the
following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Accelerated Purchase Share Amount</U>&#148; means, with respect to any Accelerated Purchase made
pursuant to Section&nbsp;2(b) hereof, the number of Purchase Shares directed by the Company to be purchased by the Investor on an Accelerated Purchase Notice, which number of Purchase Shares shall not exceed the lesser of (i)&nbsp;200% of the number
of Purchase Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular Purchase referred to in Section&nbsp;2(b) hereof (subject to the Purchase Share
limitations contained in Section&nbsp;2(a) hereof) and (ii)&nbsp;the Accelerated Purchase Share Percentage multiplied by the trading volume of the Common Shares on the Principal Market during normal trading hours on the Accelerated Purchase Date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Accelerated Purchase Date</U>&#148; means, with respect to any Accelerated Purchase made pursuant to Section&nbsp;2(b)
hereof, the Business Day immediately following the applicable Purchase Date with respect to the corresponding Regular Purchase referred to in Section&nbsp;2(b) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Accelerated Purchase Notice</U>&#148; means, with respect to any Accelerated Purchase made pursuant to Section&nbsp;2(b) hereof,
an irrevocable written notice from the Company to the Investor directing the Investor to buy a specified Accelerated Purchase Share Amount on the applicable Accelerated Purchase Date pursuant to Section&nbsp;2(b) hereof at the applicable Accelerated
Purchase Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Accelerated Purchase Share Percentage</U>&#148; means, with respect to any Accelerated Purchase made
pursuant to Section&nbsp;2(b) hereof, 30%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Accelerated Purchase Price</U>&#148; means, with respect to any particular
Accelerated Purchase made pursuant to Section&nbsp;2(b) hereof, the lower of (i)&nbsp;ninety-five percent (95%)&nbsp;of the VWAP during (A)&nbsp;the entire trading day on the Accelerated Purchase Date, if the volume of Common Shares traded on the
Principal Market on the Accelerated Purchase Date has not exceeded the Accelerated Purchase Share Volume Maximum, or (B)&nbsp;the portion of the trading day of the Accelerated Purchase Date (calculated starting at the beginning of normal trading
hours) until such time at which the volume of Common Shares traded on the Principal Market has exceeded the Accelerated Purchase Share Volume Maximum or (ii)&nbsp;the Closing Sale Price on the Accelerated Purchase Date (to be appropriately adjusted
for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
&#147;<U>Accelerated Purchase Share Volume Maximum</U>&#148; means the number of Common Shares traded on the Principal Market during normal trading hours on the Accelerated Purchase Date equal to (i)&nbsp;the amount of Common Shares properly
directed by the Company to be purchased on the Accelerated Purchase Notice, divided by (ii)&nbsp;the Accelerated Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split,
reverse stock split or other similar transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Available Amount</U>&#148; means, initially, US$26,000,000 in the
aggregate, which amount shall be reduced by the Purchase Amount each time the Investor purchases Common Shares pursuant to Section&nbsp;2 hereof, including, without limitation, the Initial Purchase pursuant to Section&nbsp;2(a) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;<U>Average Price</U>&#148; means a price per Purchase Share (rounded to the nearest
tenth of a cent) equal to the quotient obtained by dividing (i)&nbsp;the aggregate gross purchase price paid by the Investor for all Purchase Shares purchased pursuant to this Agreement, by (ii)&nbsp;the aggregate number of Purchase Shares issued
pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Bankruptcy Law</U>&#148; means the Bankruptcy and Insolvency Act (R.S.C. 1985, c. B-3), Title
11, U.S. Code, or any similar federal, state, provincial or foreign law for the relief of debtors and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;<U>Base Price</U>&#148; means a price per Purchase Share equal to the sum of (i)&nbsp;the Signing Market Price and (ii)&nbsp;$0.0619
(subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction that occurs on or after the date of this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#147;<U>Business Day</U>&#148; means any day on which the Principal Market is open for trading, including any day on which the Principal
Market is open for trading for a period of time less than the customary time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;<U>Closing Sale Price</U>&#148; means, for any
security as of any date, the last closing sale price for Common Shares on the Principal Market as reported by the Principal Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)
&#147;<U>Confidential Information</U>&#148; means any information disclosed by either party to the other party, either directly or indirectly, in writing, orally or by inspection of tangible objects (including, without limitation, documents,
prototypes, samples, plant and equipment), which is designated as &#147;Confidential,&#148; &#147;Proprietary&#148; or some similar designation. Information communicated orally shall be considered Confidential Information if such information is
confirmed in writing as being Confidential Information within ten (10)&nbsp;Business Days after the initial disclosure. Confidential Information may also include information disclosed to a disclosing party by third parties. Confidential Information
shall not, however, include any information which (i)&nbsp;was publicly known and made generally available in the public domain prior to the time of disclosure by the disclosing party; (ii)&nbsp;becomes publicly known and made generally available
after disclosure by the disclosing party to the receiving party through no action or inaction of the receiving party; (iii)&nbsp;is already in the possession of the receiving party at the time of disclosure by the disclosing party as shown by the
receiving party&#146;s files and records immediately prior to the time of disclosure; (iv)&nbsp;is obtained by the receiving party from a third party without a breach of such third party&#146;s obligations of confidentiality; (v)&nbsp;is
independently developed by the receiving party without use of or reference to the disclosing party&#146;s Confidential Information, as shown by documents and other competent evidence in the receiving party&#146;s possession; or (vi)&nbsp;is required
by law to be disclosed by the receiving party, provided that the receiving party gives the disclosing party prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information from
public disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) &#147;<U>Custodian</U>&#148; means any receiver, trustee, assignee, liquidator or similar official under any
Bankruptcy Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) &#147;<U>DTC</U>&#148; means The Depository Trust Company, or any successor performing substantially the same
function for the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) &#147;<U>DWAC Shares</U>&#148; means Common Shares that are (i)&nbsp;issued in electronic form,
(ii)&nbsp;within the United States of America, freely tradable and transferable and without restriction on resale and (iii)</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
credited by the Company to the Investor&#146;s or its designee&#146;s specified Deposit/Withdrawal at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program
or any similar program hereafter adopted by DTC performing substantially the same function. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) &#147;<U>Exchange Act</U>&#148; means the
U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) &#147;<U>Material Adverse
Effect</U>&#148; means any material adverse effect on (i)&nbsp;the enforceability of any Transaction Document, (ii)&nbsp;the results of operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, other
than any material adverse effect that resulted principally from (A)&nbsp;any change in the United States or Canadian economies or securities or financial markets in general that does not have a disproportionate effect on the Company and its
Subsidiaries, taken as a whole, (B)&nbsp;any change that generally affects the industry in which the Company and its Subsidiaries operate that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole,
(C)&nbsp;any change arising in connection with earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or terrorism or military actions
existing as of the date hereof, (D)&nbsp;any action taken by the Investor, its affiliates or its or their successors and assigns with respect to the transactions contemplated by this Agreement, (E)&nbsp;the effect of any change in applicable laws or
accounting rules that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, or (F)&nbsp;any change resulting from compliance with terms of this Agreement or the consummation of the transactions contemplated
by this Agreement, or (iii)&nbsp;the Company&#146;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document to be performed as of the date of determination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) &#147;<U>Maturity Date</U>&#148; means the first day of the month immediately following the thirty (30)&nbsp;month anniversary of the
Commencement Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) &#147;<U>Person</U>&#148; means an individual or entity, including, but not limited to, any limited liability
company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) &#147;<U>Principal Market</U>&#148; means The NASDAQ Capital Market; provided, however, that in the event the Common Shares are ever not
listed or traded on The NASDAQ Capital Market and are listed or traded on The NASDAQ Global Market, The NASDAQ Global Select Market, the New York Stock Exchange, the NYSE MKT, the NYSE Arca or the OTC Bulletin Board (it being understood that as used
herein &#147;OTC Bulletin Board&#148; shall also mean any successor or comparable market quotation system or exchange to the OTC Bulletin Board such as the OTCQB operated by the OTC Markets Group, Inc.), then the &#147;Principal Market&#148; shall
mean such other market or exchange on which the Common Shares are then listed or traded (it being hereby acknowledged and agreed that the term &#147;Principal Market&#148; for all purposes of this Agreement and the transactions contemplated hereby
shall not include the Toronto Stock Exchange (the &#147;<U>TSX</U>&#148;) or any other Canadian stock exchange or quotation system). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)
&#147;<U>Purchase Amount</U>&#148; means, with respect to the Initial Purchase, any Regular Purchase or any Accelerated Purchase made hereunder, the portion of the Available Amount to be purchased by the Investor pursuant to Section&nbsp;2 hereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) &#147;<U>Purchase Date</U>&#148; means, with respect to any particular Regular Purchase or Accelerated Purchase, as applicable, made
pursuant to Section&nbsp;2 hereof, either (i)&nbsp;the Business Day on which the Investor receives a valid Regular Purchase Notice or Accelerated Purchase Notice that the Investor is to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
buy Purchase Shares pursuant to Section&nbsp;2 hereof, if such Regular Purchase Notice or Accelerated Purchase Notice is received by the Investor between 4:01 p.m., Eastern time, and 6:00 p.m.,
Eastern time, on such Business Day, or (ii)&nbsp;the Business Day immediately prior to the Business Day on which the Investor receives a valid Regular Purchase Notice or Accelerated Purchase Notice that the Investor is to buy Purchase Shares
pursuant to Section&nbsp;2 hereof, if such Regular Purchase Notice or Accelerated Purchase Notice is received by the Investor between 8:00 a.m., Eastern time, and 9:00 a.m., Eastern time, on such Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) &#147;<U>Purchase Price</U>&#148; means, with respect to any Regular Purchase made pursuant to Section&nbsp;2(a) hereof, the lower of:
(i)&nbsp;the lowest Sale Price on the applicable Purchase Date and (ii)&nbsp;the arithmetic average of the three (3)&nbsp;lowest Closing Sale Prices for the Common Shares during the twelve (12)&nbsp;consecutive Business Days ending on the Business
Day immediately preceding such Purchase Date (in each case, to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction that occurs on or after the date of this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) &#147;<U>Regular Purchase Notice</U>&#148; means, with respect to any Regular Purchase pursuant to Section&nbsp;2(a) hereof, an
irrevocable written notice from the Company to the Investor directing the Investor to buy such applicable amount of Purchase Shares at the applicable Purchase Price as specified by the Company therein on the Purchase Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) &#147;<U>Sale Price</U>&#148; means any trade price for the Common Shares on the Principal Market as reported by the Principal Market.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) &#147;<U>Securities</U>&#148; means, collectively, the Purchase Shares and the Commitment Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) &#147;<U>Signing Market Price</U>&#148; means $1.73, representing the consolidated closing bid price of the Common Shares on The NASDAQ
Capital Market on the Business Day immediately preceding the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) &#147;<U>Subsidiary</U>&#148; means any Person
the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting stock or similar voting interest, in each case that would be disclosable pursuant to Item&nbsp;601(b)(21) of Regulation S-K
promulgated under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) &#147;<U>Transaction Documents</U>&#148; means, collectively, this Agreement and the schedules
and exhibits hereto, and each of the other agreements, documents, certificates and instruments entered into or furnished by the parties hereto in connection with the transactions contemplated hereby and thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) &#147;<U>Transfer Agent</U>&#148; means Computershare Trust Company of Canada, or such other Person who is then serving as the transfer
agent for the Company in respect of the Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) &#147;<U>VWAP</U>&#148; means in respect of an applicable Accelerated
Purchase Date, the volume weighted average price of the Common Shares on the Principal Market, as reported on the Principal Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PURCHASE OF COMMON SHARES. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in this
Agreement, the Company has the right, but not the obligation, to sell to the Investor, in the Company&#146;s sole and absolute discretion, and the Investor has the obligation to purchase from the Company, Purchase Shares as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Commencement of Regular Sales of Common Shares</U>. Upon the satisfaction of the conditions set forth in Sections 7 and 8 hereof (the
&#147;<U>Commencement</U>&#148; and the date of satisfaction of such conditions the &#147;<U>Commencement Date</U>&#148;), the Investor shall purchase US$1,000,000.77 worth of Purchase Shares (such purchase the &#147;<U>Initial Purchase</U>&#148;
and such Purchase Shares are referred to herein as the &#147;<U>Initial Purchase Shares</U>&#148;) at a price equal to US$1.664 per share. Subject to Section&nbsp;9.1 of NI 44-102, beginning one (1)&nbsp;Business Day following the Commencement Date,
the Company shall have the right, but not the obligation, in the Company&#146;s sole and absolute discretion, to direct the Investor, by its delivery to the Investor of a Regular Purchase Notice from time to time, and the Investor thereupon shall
have the obligation, to purchase up to 100,000 Purchase Shares (each such purchase a &#147;<U>Regular Purchase</U>&#148;), at the Purchase Price on the Purchase Date; provided, however, that (i)&nbsp;the Regular Purchase may be increased to up to
150,000 Purchase Shares, provided that the Closing Sale Price of the Common Shares is not below US$2.00 on the Purchase Date and (ii)&nbsp;the Regular Purchase may be increased to up to 200,000 Purchase Shares, provided that the Closing Sale Price
of the Common Shares is not below US$3.50 on the Purchase Date (all of which share amounts shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction); and provided, further,
that the Investor&#146;s committed obligation under any single Regular Purchase shall not exceed US$1,000,000, unless the parties mutually agree to increase the dollar amount of any Regular Purchase on any Purchase Date at the applicable Purchase
Price. If the Company delivers any Regular Purchase Notice for a Purchase Amount in excess of the limitations contained in the immediately preceding sentence, such Regular Purchase Notice shall be void <I>ab initio</I> to the extent of the amount by
which the number of Purchase Shares set forth in such Regular Purchase Notice exceeds the number of Purchase Shares which the Company is permitted to include in such Regular Purchase Notice in accordance herewith, and the Investor shall have no
obligation to purchase such excess Purchase Shares in respect of such Regular Purchase Notice; provided that the Investor shall remain obligated to purchase the number of Purchase Shares which the Company is permitted to include in such Regular
Purchase Notice. The Company may deliver a Regular Purchase Notice only between 4:01 p.m., Eastern time, and 6:00 p.m., Eastern time, on the applicable Purchase Date or between 8:00 a.m., Eastern time, and 9:00 a.m., Eastern time, on the Business
Day next following the applicable Purchase Date. The Company may deliver multiple Regular Purchase Notices to the Investor so long as at least one (1)&nbsp;Business Day has passed since the most recent Regular Purchase was completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Accelerated Purchases</U>. Subject to the terms and conditions of this Agreement, in addition to Regular Purchases as described in
Section&nbsp;2(a) above, the Company shall also have the right, but not the obligation, in the Company&#146;s sole and absolute discretion, to direct the Investor, by the Company&#146;s delivery to the Investor of an Accelerated Purchase Notice from
time to time, and the Investor thereupon shall have the obligation, to buy Purchase Shares at the Accelerated Purchase Price on the Accelerated Purchase Date in an amount equal to the Accelerated Purchase Share Amount; provided that the parties may
mutually agree to increase the amount of Purchase Shares sold to the Investor on any Accelerated Purchase Date at the Accelerated Purchase Price (each such purchase, an &#147;<U>Accelerated Purchase</U>&#148;). The Company may deliver an Accelerated
Purchase Notice to the Investor only on a Purchase Date on which the Company also properly submitted a Regular Purchase Notice for a Regular Purchase, pursuant to and in accordance with Section&nbsp;2(a) hereof, and the Closing Sale Price is not
below US$1.50 (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction). If the Company delivers any Accelerated Purchase Notice for an Accelerated Purchase Share Amount in
excess of the limitations contained in the definition of Accelerated Purchase Share Amount, such Accelerated Purchase Notice shall be void <I>ab initio</I> to the extent of the amount by which the number of Purchase Shares set forth in such
Accelerated Purchase Notice exceeds the Accelerated Purchase Share Amount which the Company is permitted to include in such Accelerated Purchase Notice in accordance herewith (which shall be confirmed in an Accelerated Purchase Confirmation (defined
below)), and the Investor shall have no obligation to purchase such excess </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Purchase Shares in respect of such Accelerated Purchase Notice; provided that the Investor shall remain obligated to purchase the Accelerated Purchase Share Amount which the Company is permitted
to include in such Accelerated Purchase Notice. Upon completion of each Accelerated Purchase Date, the Accelerated Purchase Share Amount and the applicable Accelerated Purchase Price shall be set forth on a confirmation of the Accelerated Purchase
to be provided to the Company by the Investor (an &#147;<U>Accelerated Purchase Confirmation</U>&#148;). The Company may deliver an Accelerated Purchase Notice only between 4:01 p.m., Eastern time, and 6:00 p.m., Eastern time, on the applicable
Purchase Date or between 8:00 a.m., Eastern time, and 9:00 a.m., Eastern time, on the Business Day next following the applicable Purchase Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Payment for Purchase Shares.</U> For each Regular Purchase and Accelerated Purchase, as applicable, (i)&nbsp;the Investor shall pay to
the Company an amount equal to the Purchase Amount with respect to such Regular Purchase and Accelerated Purchase, as applicable, as full payment for the Purchase Shares to be purchased by the Investor in connection therewith, via wire transfer of
immediately available funds to an account as the Company may from time to time designate by written notice in accordance with this Agreement, no later than one (1)&nbsp;Business Day following the applicable Purchase Date or Accelerated Purchase Date
as the case may be, and (ii)&nbsp;the Company shall direct the Transfer Agent to issue and electronically transfer all of such Purchase Shares as DWAC Shares to an account or accounts specified in writing by the Investor to the Company, no later
than one (1)&nbsp;Business Day following the receipt by the Company of the payment referred to in clause (i)&nbsp;of this sentence. If the Company or the Transfer Agent shall fail for any reason or for no reason to electronically transfer any
Purchase Shares as DWAC Shares in respect of an Accelerated Purchase within one (1)&nbsp;Business Day following the receipt by the Company of the payment therefor referred to in clause (i)&nbsp;of the immediately preceding sentence in compliance
with this Section&nbsp;2(c), and if on or after such Business Day the Investor purchases (in an open market transaction or otherwise) Common Shares to deliver in satisfaction of a sale by the Investor of such Purchase Shares that the Investor
anticipated receiving from the Company in respect of such Accelerated Purchase, then the Company shall, within three (3)&nbsp;Business Days after the Investor&#146;s request, either (i)&nbsp;pay cash to the Investor in an amount equal to the
Investor&#146;s total purchase price (including brokerage commissions, if any) for the Common Shares so purchased (the &#147;<U>Cover Price</U>&#148;), at which point the Company&#146;s obligation to deliver such Purchase Shares as DWAC Shares shall
terminate, or (ii)&nbsp;promptly honor its obligation to deliver to the Investor such Purchase Shares as DWAC Shares and pay cash to the Investor in an amount equal to the excess (if any) of the Cover Price over the total Accelerated Purchase Price
for such Accelerated Purchase. The Company shall not issue any fraction of a Common Share upon any Regular Purchase or Accelerated Purchase. If the issuance would result in the issuance of a fraction of a Common Share, the Company shall round such
fraction of a Common Share up or down to the nearest whole share. All payments made under this Agreement shall be made in lawful money of the United States of America or wire transfer of immediately available funds to such account as the Company may
from time to time designate by written notice in accordance with the provisions of this Agreement. Whenever any amount expressed to be due by the terms of this Agreement is due on any day that is not a Business Day, the same shall instead be due on
the next succeeding day that is a Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Purchase Price Floor; No Sales on TSX.</U> The Company and the Investor shall not
effect any Regular Purchase under this Agreement on any Purchase Date that the Closing Sale Price is less than the Floor Price. &#147;<U>Floor Price</U>&#148; means US$1.00, which shall be appropriately adjusted for any reorganization,
recapitalization, non-cash dividend, stock split or other similar transaction and, effective upon the consummation of any such reorganization, recapitalization, non-cash dividend, stock split or other similar transaction, the Floor Price shall mean
the <U>lower</U> of (i)&nbsp;the adjusted price and (ii)&nbsp;US$1.00. The Company and the Investor acknowledge and agree that no Securities that may be issued pursuant to this Agreement will be offered for sale or sold on the TSX. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Compliance with Rules of Principal Market and TSX</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Exchange Cap</U>. Subject to Section&nbsp;2(e)(ii) below, the Company shall not issue or sell any Common Shares pursuant to this
Agreement, and the Investor shall not purchase or acquire any Common Shares pursuant to this Agreement, to the extent that after giving effect thereto, the aggregate number of Common Shares that would be issued pursuant to this Agreement would
exceed the maximum number of Common Shares that the Company may issue pursuant to this Agreement and the transactions contemplated hereby (taking into account all Common Shares issued or issuable pursuant to any transaction or series of transactions
that may be aggregated with the transactions contemplated by this Agreement under applicable rules of The NASDAQ Stock Market) without (A)&nbsp;breaching the Company&#146;s obligations under the applicable rules of The NASDAQ Stock Market or
(B)&nbsp;obtaining shareholder approval under the applicable rules of The NASDAQ Stock Market (the &#147;<U>Exchange Cap</U>&#148;), unless and until the Company elects to solicit shareholder approval of the transactions contemplated by this
Agreement and the shareholders of the Company have in fact approved the transactions contemplated by this Agreement in accordance with the applicable rules and regulations of The NASDAQ Stock Market and the constating documents of the Company. For
the avoidance of doubt, the Company may, but shall be under no obligation to, request its shareholders to approve the transactions contemplated by this Agreement; provided, that if shareholder approval is not obtained in accordance with this
Section&nbsp;2(e)(i), the Exchange Cap shall be applicable for all purposes of this Agreement and the transactions contemplated hereby at all times during the term of this Agreement (except as set forth in Section&nbsp;2(e)(ii) below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>At-Market Transaction</U>. Notwithstanding Section&nbsp;2(e)(i) above, the Exchange Cap shall not be applicable for any purposes of
this Agreement and the transactions contemplated hereby, solely to the extent that (and only for so long as) the Average Price shall equal or exceed the Base Price (it being hereby acknowledged and agreed that the Exchange Cap shall be applicable
for all purposes of this Agreement and the transactions contemplated hereby at all other times during the term of this Agreement, unless the shareholder approval referred to in Section&nbsp;2(e)(i) is obtained). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>General</U>. The Company shall not issue any Securities pursuant to this Agreement if such issuance would reasonably be expected to
result in (A)&nbsp;a violation of the Securities Act or Canadian Securities Laws or (B)&nbsp;a breach of the rules and regulations of The NASDAQ Stock Market, or the rules and regulations of the TSX. The provisions of this Section&nbsp;2(e) shall be
implemented in a manner otherwise than in strict conformity with the terms hereof only if necessary to ensure compliance with the Securities Act, Canadian Securities Laws, the rules and regulations of The NASDAQ Stock Market, and the rules and
regulations of the TSX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Beneficial Ownership Limitation.</U> Notwithstanding anything to the contrary contained in this Agreement,
the Company shall not&nbsp;issue or sell, and the Investor shall not&nbsp;purchase or acquire, any Common Shares under this Agreement&nbsp;which, when aggregated with all other Common Shares then beneficially owned by the Investor and its affiliates
(as calculated pursuant to Section&nbsp;13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder) would result in the beneficial ownership by the&nbsp;Investor and its affiliates of more than&nbsp;9.99% of the then issued and outstanding
Common Shares (the &#147;<U>Beneficial Ownership Limitation</U>&#148;). Upon the written or oral request of the Investor, the Company shall promptly (but not later than 24 hours) confirm orally or in writing to the Investor the number of Common
Shares then outstanding. The Investor and the Company shall each cooperate in good faith in the determinations required hereby and the application hereof. The Investor&#146;s written certification to the Company of the applicability of the
Beneficial Ownership Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and such result absent manifest error. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INVESTOR&#146;S REPRESENTATIONS AND WARRANTIES. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Investor represents and warrants to
the Company that as of the date hereof and as of the Commencement Date: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Accredited Investor Status</U>. The Investor is an
&#147;accredited investor&#148; as that term is defined in Rule 501(a)(3) of Regulation D promulgated under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Information</U>. The Investor understands that its investment in the Securities involves a high degree of risk. The Investor (i)&nbsp;is able to bear the economic risk of an investment in the Securities including a total loss thereof,
(ii)&nbsp;has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the proposed investment in the Securities and (iii)&nbsp;has had an opportunity to ask questions of and receive
answers from the officers of the Company concerning the financial condition and business of the Company and others matters related to an investment in the Securities. Neither such inquiries nor any other due diligence investigations conducted by the
Investor or its representatives shall modify, amend or affect the Investor&#146;s right to rely on the Company&#146;s representations and warranties contained in Section&nbsp;4 below. The Investor has sought such accounting, legal and tax advice as
it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No
Governmental Review</U>. The Investor understands that no federal, state or provincial agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of
an investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<U>Validity; Enforcement</U>. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Investor and is a valid and binding agreement of the Investor enforceable against the Investor in accordance with its terms,
subject as to enforceability to general principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors&#146;
rights and remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Residency</U>. The Investor is a resident of the State of Illinois. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>No Short Selling</U>. The Investor represents and warrants to the Company that at no time prior to the date of this Agreement has any
of the Investor, its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any (i)&nbsp;&#147;short sale&#148; (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of
the Common Shares or (ii)&nbsp;hedging transaction, which establishes a net short position with respect to the Common Shares. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company represents and warrants to
the Investor that as of the date hereof and as of the Commencement Date: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization and Qualification</U>. The Company and each
of its Subsidiaries has been duly organized and is validly existing as a corporation in good standing under the laws of its jurisdiction with full corporate power and authority to own or lease, as the case may be, and to operate its properties and
conduct its business as described in the Prospectuses, and is duly qualified to do business as an extra-provincial corporation, where applicable, and is in good standing under the laws of each jurisdiction which requires such qualification. The
Company and each of its Subsidiaries owns or leases all such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
properties and assets as are necessary to the conduct of its operations as presently conducted free and clear of all liens, charges, encumbrances and security interests of any nature or kind. No
Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such Subsidiary&#146;s capital stock, from repaying to the Company any loans or advances to such Subsidiary
from the Company or from transferring any of such Subsidiary&#146;s property or assets to the Company or any other Subsidiary. Other than the Subsidiaries of the Company listed in Exhibit 8 to the Company&#146;s Annual Report on Form 20-F for the
fiscal year ended December&nbsp;31, 2012, the Company, directly or indirectly, owns no capital stock or other equity ownership or proprietary interest in any corporation, partnership, association, trust or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorization; Enforcement; Validity</U>. (i)&nbsp;The Company has the requisite corporate power and authority to enter into and
perform its obligations under this Agreement and each of the other Transaction Documents to which it is a party, and to issue the Securities in accordance with the terms hereof and thereof, (ii)&nbsp;the execution and delivery of the Transaction
Documents by the Company to which it is a party and the consummation by it of the transactions contemplated hereby and thereby, including without limitation, the issuance of the Commitment Shares (as defined below in Section&nbsp;5(e)) and the
reservation for issuance and the issuance of the Purchase Shares issuable under this Agreement, have been duly authorized by the Company&#146;s Board of Directors and no further consent or authorization is required by the Company, its Board of
Directors or its shareholders, (iii)&nbsp;this Agreement has been, and each other Transaction Document shall be on the Commencement Date, duly executed and delivered by the Company and (iv)&nbsp;this Agreement constitutes, and each other Transaction
Document upon its execution on behalf of the Company, shall constitute, the valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability may be limited by general
principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors&#146; rights and remedies. The Board of Directors of the Company has
passed all applicable resolutions (the &#147;<U>Resolutions</U>&#148;) to authorize this Agreement and the transactions contemplated hereby. The Resolutions are valid, in full force and effect and have not been modified or supplemented in any
respect. The Company has delivered to the Investor a certified copy of the Resolutions passed by the Board of Directors of the Company. Except as set forth in this Agreement, no other approvals or consents of the Company&#146;s Board of Directors,
any authorized committee thereof, and/or shareholders is necessary under applicable laws and the Company&#146;s constating documents to authorize the execution and delivery of this Agreement or any of the transactions contemplated hereby, including,
but not limited to, the issuance of the Commitment Shares and the issuance of the Purchase Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Capitalization</U>. The
Company&#146;s authorized equity capitalization is as set forth in the Prospectuses. The share capital of the Company conforms in all material respects to the description thereof contained in the Prospectuses. The outstanding Common Shares have been
duly authorized and validly issued and are fully paid and non-assessable. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into
or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those accurately described in all material respects in the Prospectuses. The description of the Company&#146;s option, bonus and other share
plans or arrangements, and the options or other rights granted thereunder, set forth in the Prospectuses accurately and fairly presents in all material respects the information required to be shown with respect to such plans, arrangements, options
and rights. No holders of securities of the Company have rights to the registration of such securities under the Registration Statement or the qualification of such securities under the Canadian Prospectuses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Issuance of Securities</U>. Upon issuance and payment thereof in accordance with the terms and conditions of this Agreement, the
Purchase Shares shall be validly issued, fully paid and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nonassessable and free from all taxes, liens, charges, restrictions, rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights
accorded to a holder of Common Shares. The Purchase Shares and the Commitment Shares (as defined below in Section&nbsp;5(e)) have been duly authorized and reserved for issuance and, upon issuance in accordance with the terms of this Agreement, shall
be validly issued, fully paid and nonassessable and free from all taxes, liens, charges, restrictions, rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights accorded to a
holder of Common Shares. The Securities are being issued pursuant to the Registration Statement and the issuance of the Securities has been registered by the Company pursuant to the Securities Act. Upon receipt of the Purchase Shares and the
Commitment Shares, the Investor will have good and marketable title to such Securities and such Securities will be immediately freely tradable in the United States on the Principal Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>No Conflicts</U>. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby (including, without limitation, the reservation for issuance and issuance of the Purchase Shares and the Commitment Shares) will not (i)&nbsp;result in a violation of the constating
documents of the Company or any of its Subsidiaries or (ii)&nbsp;conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or result in a violation of any law, rule, regulation, order, judgment or decree (including, without limitation, U.S.
federal and state securities laws and regulations, Canadian Securities Laws and the rules and regulations of the Principal Market and the TSX) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or
any of its Subsidiaries is bound or affected, except in the case of conflicts, defaults, terminations, amendments, accelerations, cancellations and violations under clause (ii), which could not reasonably be expected to result in a Material Adverse
Effect. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default under its constating documents. Neither the Company nor any of its Subsidiaries is in violation of any term of or is in default under any material
contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or regulation applicable to the Company or its Subsidiaries, except for possible conflicts, defaults, terminations or amendments that
could not reasonably be expected to have a Material Adverse Effect. The business of the Company and its Subsidiaries is not being conducted, and shall not be conducted, in violation of any law, ordinance, regulation of any governmental entity,
except for possible violations, the sanctions for which either individually or in the aggregate could not reasonably be expected to have a Material Adverse Effect. No consent, approval, authorization, filing with or order of any court or
governmental agency or body is required in connection with the transactions contemplated herein, except such as have been obtained under the Securities Act, the Exchange Act and Canadian Securities Laws, and such as may be required under the blue
sky laws of any jurisdiction or the rules and regulations of the Financial Industry Regulatory Authority (&#147;<U>FINRA</U>&#148;), the Principal Market or the TSX in connection with the transactions contemplated by this Agreement. Except as set
forth elsewhere in this Agreement, all consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence shall be obtained or effected on or prior to the Commencement Date. Since
one year prior to the date hereof, the Company has not received nor delivered any notices or correspondence from or to the Principal Market or the TSX relating to any violation of the listing requirements of the Principal Market or the TSX. Neither
the Principal Market nor the TSX has commenced any delisting proceedings against the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>SEC Documents; Financial
Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a) or 15(d) thereof, for the
twelve months preceding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated
by reference therein, being collectively referred to herein as the &#147;<U>SEC Documents</U>&#148;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Documents prior to the expiration of any such
extension.&nbsp;As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable. None of the SEC Documents, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Except as set forth in the SEC
Documents, the Company has received no notices or correspondence from the SEC for the one year preceding the date hereof<B>.</B> The SEC has not commenced any enforcement proceedings against the Company or any of its Subsidiaries. The financial
statements of the Company and its consolidated Subsidiaries, together with the related notes, set forth or incorporated by reference in the Prospectuses and the Registration Statement present fairly the financial condition, results of operations and
cash flows of the Company as of the dates and for the periods indicated, comply as to form with the applicable accounting requirements of the Securities Act, the Exchange Act, and applicable Canadian Securities Laws and have been prepared in
conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board, applied on a consistent basis throughout the periods involved (except as otherwise noted therein). There has been no material
change in accounting policies or practices of the Company since December&nbsp;31, 2012. There are no &#147;significant acquisitions&#148;, &#147;significant dispositions&#148; or &#147;significant probable acquisitions&#148; for which the Company is
required, pursuant to Canadian Securities Laws, to include additional financial disclosure in the Prospectuses. All non-GAAP financial information included in the Registration Statement and the Prospectuses complies with the requirements of
Regulation G under the Securities Act and Canadian Securities Laws regarding the use of non-GAAP financial information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Absence of
Certain Changes</U>. Except as disclosed in the SEC Documents, since December&nbsp;31, 2012, there has been no material adverse change in the business, properties, operations, financial condition or results of operations of the Company or its
Subsidiaries. The Company is not in violation or default of (i)&nbsp;any provision of its constating documents, (ii)&nbsp;the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement,
obligation, condition, covenant or instrument to which it is a party or bound or to which its property is subject, or (iii)&nbsp;any statute, law, rule, regulation, judgment, order or decree of any court, regulatory body, administrative agency,
governmental body, arbitrator or other authority having jurisdiction over the Company or any of its properties, which, in the case of clauses (ii)&nbsp;or (iii), could be reasonably expected to have a Material Adverse Effect. Except as described in
the Prospectuses, no dispute between the Company and any local, native, aboriginal or indigenous group exists or, to the knowledge of the Company, is threatened or imminent that could reasonably be expected to have a Material Adverse Effect. The
Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to
initiate involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as they become due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Absence of Litigation</U>. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board,
government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against or affecting the Company, the Common Shares or any of the Company&#146;s or its Subsidiaries&#146;
officers or directors in their capacities as such, which could reasonably be expected to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Acknowledgment Regarding Investor&#146;s Status</U>. The Company acknowledges and agrees
that the Investor is acting solely in the capacity of arm&#146;s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that the Investor is not acting as a
financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor or any of its representatives or agents in
connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to the Investor&#146;s purchase of the Securities. The Company further represents to the Investor that the Company&#146;s decision to
enter into the Transaction Documents has been based solely on the independent evaluation by the Company and its representatives and advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>No Integrated Offering</U>. None the Company, any of its affiliates, or any authorized Person acting on its or their behalf has,
directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company in a manner that
would require shareholder approval pursuant to the rules of the Principal Market on which any of the securities of the Company are listed or designated or the TSX. The issuance and sale of the Securities hereunder does not contravene the rules and
regulations of the Principal Market or the TSX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Intellectual Property Rights</U>. The Company and its Subsidiaries own or possess
adequate rights or licenses to use all material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and
rights necessary to conduct their respective businesses as now conducted. None of the Company&#146;s material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions,
licenses, approvals, government authorizations, trade secrets or other intellectual property rights have expired or terminated, or, by the terms and conditions thereof, could expire or terminate within two years from the date of this Agreement. The
Company and its Subsidiaries do not have any knowledge of any infringement by the Company or its Subsidiaries of any material trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks,
service mark registrations, trade secret or other similar rights of others, or of any such development of similar or identical trade secrets or technical information by others, and there is no claim, action or proceeding being made or brought
against, or to the Company&#146;s knowledge, being threatened against, the Company or its Subsidiaries regarding trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks, service mark registrations,
trade secret or other infringement, which could reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Environmental Laws</U>.
The Company and its Subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign, federal, state, provincial and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants (&#147;<U>Environmental Laws</U>&#148;), (ii)&nbsp;have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses
and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval, except where, in each of the three foregoing clauses, the failure to so comply could not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Title</U>. The Company and its Subsidiaries have good and marketable title in fee simple to
all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects
(&#147;<U>Liens</U>&#148;) and, except for Liens as do not materially affect the value of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property and do not materially interfere with the use made and proposed to be made of such property by the Company and its Subsidiaries and Liens for the payment of federal, state, provincial or
other taxes, the payment of which is neither delinquent nor subject to penalties.&nbsp;Any real property and facilities held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with which
the Company and its Subsidiaries are in compliance with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Insurance</U>. The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any
insurance coverage sought or applied for and neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business at a cost that would not materially and adversely affect the condition, financial or otherwise, or the earnings, business or operations of the Company and its Subsidiaries, taken as a
whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Regulatory Permits</U>. The Company and its Subsidiaries possess all material certificates, authorizations and permits
issued by the appropriate federal, state, provincial, local or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any such Subsidiary has received any notice of proceedings relating to the
revocation or modification of any such certificate, authorization or permit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Tax Status</U>. Each of the Company and the
Subsidiaries has filed all federal, state, provincial, local and foreign tax returns that are required to be filed or has requested extensions thereof (except in any case in which the failure so to file would not have a Material Adverse Effect) and
has paid all taxes required to be paid by it and any other assessment, fine or penalty levied against it, to the extent that any of the foregoing is due and payable, except for any such assessment, fine or penalty that is currently being contested
in good faith or as would not have a Material Adverse Effect. There are no transfer taxes or other similar fees or charges under Canadian or U.S. federal law or the laws of any state, province, territory or any political subdivision thereof,
required to be paid in connection with the execution and delivery of this Agreement or the issuance by the Company or sale by the Company of the Common Shares. No stamp duty, registration or documentary taxes, duties or similar charges are payable
under the federal laws of Canada or the laws of any province in connection with the creation, issuance, sale and delivery by the Company of the Common Shares or the authorization, execution, delivery and performance of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Transactions With Affiliates</U>. Except as set forth in the SEC Documents, none of the officers or directors of the Company and, to
the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors) that is required to be disclosed and is not
disclosed, including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or
such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $120,000 other than for
(i)&nbsp;payment of salary or consulting fees for services rendered, (ii)&nbsp;reimbursement for expenses incurred on behalf of the Company and (iii)&nbsp;other employee benefits, including stock option agreements under any stock option plan of the
Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Application of Takeover Protections</U>. The Company and its board of directors have taken
or will take prior to the Commencement Date all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision which is or could become applicable to the Investor as a result of the transactions contemplated by this Agreement, including, without limitation, the Company&#146;s issuance of the Securities and the Investor&#146;s
ownership of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Disclosure</U>.&nbsp;Except with respect to the material terms and conditions of the transactions
contemplated by the Transaction Documents that will be timely publicly disclosed by the Company, the Company confirms that neither it nor any other Person acting on its behalf has provided the Investor or its agents or counsel with any information
that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectuses or the SEC Documents.&nbsp;The Company understands and confirms that the Investor will rely on the foregoing
representation in effecting purchases and sales of securities of the Company.&nbsp;All of the disclosure furnished by or on behalf of the Company to the Investor regarding the Company, its business and the transactions contemplated hereby, including
the disclosure schedules to this Agreement, is true and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light
of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made and when made, not misleading.&nbsp;The Company acknowledges and agrees that
the Investor neither makes nor has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section&nbsp;3 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Foreign Corrupt Practices; Money Laundering Laws; Sanctions</U>. Neither the Company nor any of the Subsidiaries nor, to the knowledge
of the Company, any director, officer, agent, employee or affiliate of the Company or any of the Subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt
Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#147;<U>FCPA</U>&#148;) or the Corruption of Foreign Public Officials Act (Canada) (the &#147;<U>CFPOA</U>&#148;), including, without limitation, making use of the
mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of
anything of value to any &#147;foreign official&#148; (as such term is defined in the FCPA or the CFPOA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA; and the Company,
the Subsidiaries and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and the CFPOA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably
expected to continue to ensure, continued compliance therewith. The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements and the
money laundering statutes and the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any applicable governmental agency, including, without limitation, Title 18 U.S. Code
section 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the
United States is a member and with which designation the United States representative to the group or organization continues to concur, all as amended, and any Executive order, directive or regulation pursuant to the authority of any of the
foregoing, or any orders or licenses issued thereunder (collectively, the &#147;<U>Money Laundering Laws</U>&#148;), and no action, suit or proceeding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the
best knowledge of the Company, threatened. Neither the Company nor any of its Subsidiaries, nor to the knowledge of the Company any of the directors, officers or employees, agents, affiliates or representatives of the Company or its Subsidiaries, is
an individual or entity that is, or is owned or controlled by an individual or entity that is: (i)&nbsp;the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#146;s Office of Foreign Assets Control, the United
Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;<U>Sanctions</U>&#148;), nor (ii)&nbsp;located, organized or resident in a country or territory that is the subject
of Sanctions (including, without limitation, Burma/Myanmar, Cuba, Iran, Libya, North Korea, Sudan and Syria). Neither the Company nor any of its Subsidiaries will, directly or indirectly, use the proceeds of the offering, or lend, contribute or
otherwise make available such proceeds to any subsidiary, joint venture partner or other individual or entity: (i)&nbsp;to fund or facilitate any activities or business of or with any individual or entity or in any country or territory that, at the
time of such funding or facilitation, is the subject of Sanctions or (ii)&nbsp;in any other manner that will result in a violation of Sanctions by any individual or entity (including any individual or entity participating in the offering, whether as
underwriter, advisor, investor or otherwise). For the past five years, neither the Company nor any of its Subsidiaries has knowingly engaged in, and is not now knowingly engaged in, any dealings or transactions with any individual or entity, or in
any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Registration
Statement; Prospectuses</U>. The Company meets the general eligibility requirements for the use of National Instrument 44-101 &#150; <I>Short Form Prospectus Distributions</I> and NI 44-102 and for the use of a short form base shelf prospectus with
respect to a distribution of securities. The Reviewing Authority has issued the Receipt on behalf of itself and the other Qualifying Authorities for the Canadian Base Prospectus. Subsequent to the issuance of the Receipt for the Canadian Base
Prospectus, no other document with respect to the Canadian Base Prospectus has heretofore been filed with the Qualifying Authorities, except for any document filed with the Qualifying Authorities subsequent to the date of such Receipt in the form
heretofore delivered to the Investor. No order, ruling or determination having the effect of suspending the sale or ceasing the trading of the Common Shares or any other securities of the Company has been issued or made by any Canadian Qualifying
Authority, any other securities commission, stock exchange or other regulatory authority and no proceedings for that purpose have been initiated or are pending or, to the best of the Company&#146;s knowledge, are contemplated or threatened by any
Canadian Qualifying Authority, any other securities commission, stock exchange or other regulatory authority, and any request made to the Company on the part of any Canadian Qualifying Authority, any other securities commission, stock exchange or
other regulatory authority for additional information has been complied with. At the time of filing the Registration Statement the Company met, and as of the date hereof the Company meets, the general eligibility requirements for use of Form F-10
under the Securities Act. The Registration Statement has become effective pursuant to Rule 467(b) under the Securities Act. The Company has complied to the SEC&#146;s satisfaction with all requests of the SEC for additional or supplemental
information. No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for that purpose have been initiated or are pending or, to the best of the Company&#146;s knowledge, are contemplated or threatened
by the SEC, and any request made to the Company on the part of the SEC for additional information has been complied with. The Canadian Prospectuses, at the time of filing thereof with the Qualifying Authorities, complied and, as amended or
supplemented, if applicable, will comply in all material respects with Canadian Securities Laws. The Canadian Prospectuses, as amended or supplemented, as of their respective dates, did not and, as of each Purchase Date, if any, will not contain a
misrepresentation, as defined under Canadian Securities Laws, or include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the circumstances under which they were made, not misleading. The Canadian Prospectuses, as amended or supplemented, as of their respective dates, did and, as of each Purchase Date, if any,
will contain full, true and plain disclosure of all material facts relating to the Securities and to the Company and its Subsidiaries. The representations and warranties set forth in the two immediately preceding sentences do not apply to statements
in or omissions from the Canadian Prospectuses, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by the Investor expressly for use
therein. The U.S. Prospectuses, at the time first filed in accordance with General Instruction II.L. of Form F-10, conformed and, as amended or supplemented, if applicable, will conform in all material respects to the Canadian Prospectuses, except
for such deletions therefrom and additions thereto as are permitted or required by Form F-10 and the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied and, as of
each Purchase Date, if any, will comply in all material respects with the applicable requirements of Form F-10, the Securities Act and the Exchange Act and did not and, as of each Purchase Date, if any, will not contain any untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The U.S. Prospectuses, as amended or supplemented, as of their respective dates, did not and, as of each
Purchase Date, if any, will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The
representations and warranties set forth in the two immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the U.S. Prospectuses, or any amendments or
supplements thereto, made in reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by the Investor expressly for use therein. There is no franchise, contract or other document of a character
required to be described in the Registration Statement or the Prospectuses, or to be filed as an exhibit to the Registration Statement, which is not described or filed as required. The statistical, industry and market-related data included in the
Prospectuses is based on or derived from sources that the Company believes to be reliable and accurate, and such data agrees with the sources from which it is derived. The Company has delivered to the Investor one complete copy of each of the
Canadian Base Prospectus and the Registration Statement and a copy of each consent and certificate of experts filed as a part thereof, and conformed copies of the Canadian Base Prospectus, the Registration Statement (without exhibits) and the
Prospectuses, as amended or supplemented, in such quantities and at such places as the Investor has reasonably requested. The Company has not distributed and will not distribute any offering material in connection with the offering and sale of the
Common Shares in connection with this Agreement other than the Prospectuses or the Registration Statement. At the earliest time after the filing of the Registration Statement that the Company or another offering participant made a<I> bona fide</I>
offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Securities and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act, in the preceding three
years not having been convicted of a felony or misdemeanor or having been made the subject of a judicial or administrative decree or order as described in Rule 405 of the Securities Act (without taking account of any determination by the SEC
pursuant to Rule 405 of the Securities Act that it is not necessary that the Company be considered an ineligible issuer), nor an &#147;excluded issuer&#148; as defined in Rule 164 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>DTC Eligibility</U>. The Company, through the Transfer Agent, currently participates in the DTC Fast Automated Securities Transfer
(FAST) Program and the Common Shares can be transferred electronically to third parties via the DTC Fast Automated Securities Transfer (FAST) Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>Accounting Controls; Sarbanes-Oxley</U>. The Company maintains a system of internal accounting controls sufficient to provide
reasonable assurances that (A)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (B)&nbsp;transactions are recorded as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
necessary to permit preparation of financial statements in conformity with International Financial Reporting Standards as adopted by the International Accounting Standards Board, and to maintain
accountability for assets; (C)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (D)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Registration Statement and in the Prospectuses, the Company has concluded that its internal control over financial reporting is effective and none
of the Company, its board of directors and audit committee is aware of any &#147;significant deficiencies&#148; or &#147;material weaknesses&#148; (each as defined by the rules adopted by the SEC) in its internal control over financial reporting, or
any fraud, whether or not material, that involves management or other employees of the Company and its Subsidiaries who have a significant role in the Company&#146;s internal controls; and since the end of the latest audited fiscal year, there has
been no change in the Company&#146;s internal control over financial reporting (whether or not remediated) that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The
Company&#146;s board of directors has, subject to the exceptions, cure periods and the phase in periods specified in the applicable stock exchange rules (&#147;<U>Exchange Rules</U>&#148;), validly appointed an audit committee to oversee internal
accounting controls whose composition satisfies the applicable independence and other requirements of the Exchange Rules and Canadian Securities Laws, and the Company&#146;s board of directors and/or the audit committee has adopted a charter that
satisfies the requirements of the Exchange Rules and Canadian Securities Laws. The Company maintains disclosure controls and procedures as required by Rule l3a-15 or Rule 15d-15 under the Exchange Act and as contemplated by the certifications
required under Form 52-109F1 and Form 52-109F2 under National Instrument 52-109 &#151; <I>Certification of Disclosures in Issuer&#146;s Annual and Interim Filings</I>; the Company has concluded that such controls and procedures are effective to
ensure that all material information concerning the Company and any of its Subsidiaries is made known, on a timely basis, to the individuals responsible for the preparation of the Company&#146;s filings with the SEC and the Qualifying Authorities.
The Company has utilized such controls and procedures in preparing and evaluating the disclosures in the Registration Statement Prospectuses. Neither the Company&#146;s board of directors nor the audit committee has been informed, nor is any
director of the Company or the Company aware, of (A)&nbsp;any significant deficiencies in the design or operation of the Company&#146;s internal controls which could adversely affect the Company&#146;s ability to record, process, summarize and
report financial data or any material weakness in the Company&#146;s internal controls; or (B)&nbsp;any fraud, whether or not material, that involves management or other employees of the Company who have a significant role in the Company&#146;s
internal controls. No relationship, direct or indirect, exists between or among the Company, on the one hand, and the directors, officers, shareholders, customers or suppliers of the Company, on the other hand, which is required to be described in
the Registration Statement and the Prospectuses which is not so described. The Company has not, directly or indirectly, extended or maintained credit, or arranged for the extension of credit, or renewed an extension of credit, in the form of a
personal loan to or for any of its directors or executive officers in violation of applicable laws, including Section&nbsp;402 of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith (the
&#147;<U>Sarbanes-Oxley Act</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Certain Fees</U>. Except as disclosed on <U>Schedule 4(x)</U>, no brokerage or
finder&#146;s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction
Documents. Except as disclosed on <U>Schedule 4(x)</U>, the Investor shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section&nbsp;4(x) that
may be due in connection with the transactions contemplated by the Transaction Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>Investment Company</U>. The Company is not, and immediately after receipt of payment for
the Securities will not be, an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended (the &#147;<U>Investment Company Act</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>Canadian Reporting Issuer; Compliance With Exchange Requirements</U>. The Company is a reporting issuer (or equivalent thereof) in each
Qualifying Jurisdiction and is not on the list of defaulting reporting issuers maintained by the applicable authorities in each such Qualifying Jurisdiction that maintains such a list. The Company has not filed any confidential material changes
reports which remain confidential at the date hereof. The Common Shares are registered pursuant to Section&nbsp;12(b) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of,
terminating the registration of the Common Shares pursuant to the Exchange Act nor has the Company received any notification that the SEC is currently contemplating terminating such registration. The Common Shares are currently listed on
(i)&nbsp;the Principal Market under the trading symbol &#147;ONCY&#148; and (ii)&nbsp;the TSX under the trading symbol &#147;ONC&#148;. The Company has not, in the twelve (12)&nbsp;months preceding the date hereof, received any notice from any
Person to the effect that the Company is not in compliance with the rules and regulations of the Principal Market or the TSX. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in material
compliance with the rules and regulations of the Principal Market and the TSX. Except as described in the Registration Statement or the Prospectuses, there are no affiliations among the Company&#146;s directors and officers and members of the FINRA.
To the knowledge of the Company, no beneficial owners of the Company&#146;s capital stock or subordinated debt who, together with their associated persons and affiliates, hold in the aggregate 10% or more of such capital stock or subordinated debt,
have any direct or indirect association or affiliate with a FINRA member. A Registration Statement relating to the Common Shares on Form 8-A or other applicable form under the Exchange Act has become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>Accountants</U>. Ernst&nbsp;&amp; Young LLP, Chartered Accountants, who have audited certain financial statements of the Company and
its consolidated Subsidiaries and delivered their report with respect to the audited consolidated financial statements included or incorporated by reference in the Registration Statement and the Prospectuses, are independent public accountants with
respect to the Company within the meaning of the Securities Act and the Exchange Act and the applicable published rules and regulations thereunder and are independent with respect to the Company as required by Canadian Securities Laws. There has not
been any reportable event (within the meaning of Section&nbsp;4.11 of National Instrument 51-102 &#150; <I>Continuous Disclosure Obligations</I>) with the auditors of the Company nor any event which has led the Company&#146;s current or former
auditors to threaten to resign. The audit committee of the Company is comprised and operates in accordance with the requirements of National Instrument 52-110 &#150; <I>Audit Committees</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <U>No Market Manipulation</U>.&nbsp;The Company has not taken and will not take, directly or indirectly, any action designed to or that
would constitute or that might reasonably be expected to cause or result in, under the Exchange Act, Canadian Securities Laws or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of
the Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <U>Benefit Plans; Labor Matters</U>. Each benefit and compensation plan, agreement, policy and arrangement that
is maintained, administered or contributed to by the Company for current or former employees or directors of, or independent contractors with respect to, the Company has been maintained in compliance with its terms and the requirements of any
applicable statutes, orders, rules and regulations and the Company has complied in all material respects with all applicable statutes, orders, rules and regulations in regard to such plans, agreements, policies and arrangements. Each stock option
granted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under any stock option plan of the Company (each, a &#147;<U>Stock Plan</U>&#148;) was granted with a per share exercise price no less than the market price per common share on the grant date of
such option in accordance with the rules of the TSX, and no such grant involved any &#147;back-dating,&#148; &#147;forward-dating&#148; or similar practice with respect to the effective date of such grant; each such option (i)&nbsp;was granted in
compliance in all material respects with applicable laws and with the applicable Stock Plan(s), (ii)&nbsp;was duly approved by the Board of Directors (or a duly authorized committee thereof) of the Company, and (iii)&nbsp;has been properly accounted
for in the Company&#146;s financial statements and disclosed, to the extent required, in the Company&#146;s filings or submissions with the SEC, the Canadian Qualifying Authorities, the Principal Market and the TSX. No labor problem or dispute with
the employees of the Company exists or is threatened or imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its principal suppliers or contractors, that could have a Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <U>Regulatory</U>. Except as described in the Registration Statement and the Prospectuses, the Company and each of its
Subsidiaries: (A)&nbsp;is and at all times has been in material compliance with all applicable U.S., Canadian and foreign statutes, rules, regulations, or guidance applicable to Company and its Subsidiaries and the ownership, testing, development,
manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company (&#147;<U>Applicable Laws</U>&#148;), except
as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; (B)&nbsp;have not received any notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the U.S.
Food and Drug Administration or any other U.S. or Canadian federal, state, provincial or foreign governmental authority having authority over the Company (&#147;<U>Governmental Authority</U>&#148;) alleging or asserting noncompliance with any
Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#147;<U>Authorizations</U>&#148;); (C)&nbsp;possess all material
Authorizations and such material Authorizations are valid and in full force and effect and are not in violation of any term of any such material Authorizations; (D)&nbsp;have not received notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any Governmental Authority or third party alleging that any product operation or activity is in violation of any Applicable Laws or Authorizations and have no knowledge that any such
Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E)&nbsp;have not received notice that any Governmental Authority has taken, is taking or intends to take action
to limit, suspend, modify or revoke any Authorizations and the Company has no knowledge that any such Governmental Authority is considering such action; and (F)&nbsp;have filed, obtained, maintained or submitted all material reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or material Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission). To the Company&#146;s knowledge, the studies, tests and preclinical and clinical
trials conducted by or on behalf of the Company were and, if still pending, are, in all material respects, being conducted in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and
all applicable laws, including, without limitation, the United States Federal Food, Drug and Cosmetic Act and the laws, rules and regulations of the Therapeutic Products Directorate, the European Medicines Agency, the European Commission&#146;s
Enterprise Directorate General and the regulatory agencies within each Member State granting Marketing Authorization through the Mutual Recognition Procedure or any other federal, provincial, state, local or foreign governmental or
quasi-governmental body exercising comparable authority; the descriptions of the results of such studies, tests and trials contained in the Prospectuses are accurate and complete in all material respects and fairly present the data derived from such
studies, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tests and trials; the descriptions in the Prospectuses of the results of such clinical trials are consistent in all material respects with such results and to the Company&#146;s knowledge there
are no other studies or other clinical trials whose results are materially inconsistent with or otherwise materially call into question the results described or referred to in the Prospectuses; and the Company has not received any notices or
correspondence from any governmental authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or its Subsidiaries. The Company has
concluded that it uses commercially reasonable efforts to review, from time to time, the progress and results of the studies, tests and preclinical and clinical trials and, based upon (i)&nbsp;the information provided to the Company by the third
parties conducting such studies, tests, preclinical studies and clinical trials that are described in the Prospectuses and the Company&#146;s review of such information, and (ii)&nbsp;the Company&#146;s actual knowledge, the Company reasonably
believes that the descriptions of the results of such studies, tests, preclinical studies and clinical trials are accurate and complete in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <U>Transfer Agent and Registrar</U>. Computershare Trust Company of Canada at its principal offices in Calgary, Alberta is the duly
appointed registrar and transfer agent of the Company with respect to the outstanding Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <U>Shell Company Status</U>.
The Company is not currently, and within the past three years has not been, an issuer identified in Rule 144(i)(1) under the Securities Act. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>COVENANTS. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Filing of Current Report and Prospectuses; Issuance of Initial Press
Release</U>. The Company agrees that it shall, (i)&nbsp;within the time required under the Exchange Act, file with the SEC a report on Form 6-K relating to the transactions contemplated by the Transaction Documents (the &#147;<U>Current
Report</U>&#148;) and (ii)&nbsp;within the time required under the applicable rules of the TSX, issue a press release relating to the transactions contemplated by the Transaction Documents (the &#147;<U>Initial Press Release</U>&#148;), which
Initial Press Release shall be filed as an exhibit to the Current Report. The Company further agrees that it shall prepare the Canadian Prospectus Supplement and the U.S. Prospectus Supplement in a form approved by the Investor and shall
(A)&nbsp;file the Canadian Prospectus Supplement with each of the Canadian Qualifying Authorities in accordance with applicable Canadian Securities Laws no later than the applicable Canadian Qualifying Authority&#146;s close of business on the date
of this Agreement and (B)&nbsp;file the U.S. Prospectus Supplement with the SEC pursuant to General Instruction II.L of Form F-10 no later than the SEC&#146;s close of business on the date of this Agreement. The Company shall permit the Investor to
review and comment upon (1)&nbsp;the Current Report, the Canadian Prospectus Supplement and the U.S. Prospectus Supplement at least two (2)&nbsp;Business Days prior to their filing with the Canadian Qualifying Authorities or the SEC, as applicable,
and (2)&nbsp;the Initial Press Release at least one (1)&nbsp;Business Day prior to its issuance by the Company, the Company shall give due consideration to all such comments, and the Company shall not file the Current Report, the Canadian Prospectus
Supplement or the U.S. Prospectus Supplement with the Canadian Qualifying Authorities or the SEC, as applicable, or issue the Initial Press Release, in each case in a form to which the Investor reasonably objects. The Investor shall use its
reasonable best efforts to comment upon the Current Report, the Canadian Prospectus Supplement, the U.S. Prospectus Supplement and the Initial Press Release within one (1)&nbsp;Business Day from the date the Investor receives the final versions
thereof from the Company. The Investor shall furnish to the Company such information regarding itself, the Securities held by it and the intended method of distribution thereof as shall be reasonably requested by the Company in connection with the
preparation and filing of the Current Report, the Canadian Prospectus Supplement and the U.S. Prospectus Supplement and the preparation and issuance of the Initial Press Release, and shall otherwise cooperate with the Company as reasonably requested
by the Company in connection with the preparation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and filing of the Current Report, the Canadian Prospectus Supplement and the U.S. Prospectus Supplement with the Canadian Qualifying Authorities or the SEC, as applicable, and the preparation and
issuance of the Initial Press Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Blue Sky</U>. The Company shall take all such action, if any, as is reasonably necessary in
order to obtain an exemption for or to qualify (i)&nbsp;the issuance of the Commitment Shares and the sale of the Purchase Shares to the Investor under this Agreement and (ii)&nbsp;any subsequent resale of all Commitment Shares and all Purchase
Shares by the Investor, in each case, under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States in such states as is reasonably requested by the Investor during the Registration Period, and shall provide evidence of
any such action so taken to the Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Listing/DTC</U>. The Company shall promptly secure the listing, or conditional listing
as applicable, of all of the Purchase Shares and Commitment Shares to be issued to the Investor hereunder on the Principal Market and the TSX (subject to standard listing conditions, if any, for transactions of this nature, official notice of
issuance and the Exchange Cap) and upon each other national securities exchange or automated quotation system, if any, upon which the Common Shares are then listed, and shall maintain, so long as any Common Shares shall be so listed, such listing of
all such Securities from time to time issuable hereunder. The Company shall use commercially reasonable efforts to maintain the listing of the Common Shares on the Principal Market and shall comply in all respects with the Company&#146;s reporting,
filing and other obligations under the bylaws or rules and regulations of the Principal Market and, for so long as the Common Shares shall be listed on the TSX, shall comply in all respects with the Company&#146;s reporting, filing and other
obligations under the bylaws or rules and regulations of the TSX. Neither the Company nor any of its Subsidiaries shall take any action that would reasonably be expected to result in the delisting or suspension of the Common Shares on the Principal
Market. The Company shall promptly, and in no event later than the following Business Day, provide to the Investor copies of any notices it receives from any Person regarding the continued eligibility of the Common Shares for listing on the
Principal Market or the TSX. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section&nbsp;5(c). The Company shall take all action necessary to ensure that its Common Shares can be transferred
electronically as DWAC Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Prohibition of Short Sales and Hedging Transactions</U>. The Investor agrees that, beginning on the
date of this Agreement and ending on the date of termination of this Agreement as provided in Section&nbsp;11, the Investor and its agents, representatives and affiliates shall not in any manner whatsoever enter into or effect, directly or
indirectly, any (i)&nbsp;&#147;short sale&#148; (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Shares or (ii)&nbsp;hedging transaction, which establishes a net short position with respect to the Common
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Issuance of Commitment Shares</U>. In consideration for the Investor&#146;s execution and delivery of this Agreement, the
Company shall cause the Transfer Agent to issue, upon the purchase of the Initial Purchase Shares, 292,793 Common Shares (the &#147;<U>Initial Commitment Shares</U>&#148;) directly to the Investor electronically as DWAC Shares and shall deliver to
the Transfer Agent the Irrevocable Transfer Agent Instructions with respect to the issuance of the Initial Commitment Shares. For the avoidance of doubt, all of the Initial Commitment Shares shall be fully earned upon the purchase of the Initial
Purchase Shares, whether or not any additional Purchase Shares are purchased thereafter by the Investor under this Agreement and irrespective of any termination of this Agreement. In connection with the Initial Purchase and each Regular Purchase and
each Accelerated Purchase of Purchase Shares hereunder, the Company shall issue to the Investor a number of Common Shares (the &#147;<U>Additional Commitment Shares</U>&#148; and, collectively with the Initial Commitment Shares, the
&#147;<U>Commitment Shares</U>&#148;) equal to the product of (x)&nbsp;292,793 and (y)&nbsp;the Purchase Amount Fraction. The &#147;<U>Purchase Amount Fraction</U>&#148; shall mean a fraction, the numerator of which is the Purchase Amount purchased
by the Investor with respect to such Initial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Purchase, Regular Purchase and Accelerated Purchase (as applicable) of Purchase Shares and the denominator of which is US$26,000,000. The Commitment Shares shall be issued to the Investor on the
same Business Day as Purchase Shares are issued to the Investor in connection with the applicable Regular Purchase and Accelerated Purchase (as applicable) in accordance with Section&nbsp;2(c). The Additional Commitment Shares shall be equitably
adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction. For the avoidance of doubt, the Additional Commitment Shares shall be fully earned as of the date of their pro rata issuance as Purchase
Shares are issued to the Investor in connection with the applicable Regular Purchase and Accelerated Purchase (as applicable) in accordance with Section&nbsp;2(c), whether or not any additional Purchase Shares are purchased thereafter by the
Investor under this Agreement and irrespective of any subsequent termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Due Diligence; Non-Public
Information</U>. During the term of this Agreement, the Investor shall have the right, from time to time as the Investor may reasonably deem appropriate, to perform reasonable due diligence on the Company during normal business hours. The Company
and its officers and employees shall provide information and reasonably cooperate with the Investor in connection with any reasonable request by the Investor related to the Investor&#146;s due diligence of the Company. Each party hereto agrees not
to disclose any Confidential Information of the other party to any third party and shall not use the Confidential Information for any purpose other than in connection with, or in furtherance of, the transactions contemplated hereby. Each party
hereto acknowledges that the Confidential Information shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed by the other party. From
and after the date of this Agreement, the Company confirms that neither it nor any other Person acting on its behalf shall provide the Investor or its agents or counsel with any information that the Company believes constitutes material, non-public
information, unless a simultaneous public announcement thereof is made by the Company in the manner contemplated by Regulation FD under the Exchange Act. In the event of a breach of the foregoing covenant by the Company or any Person acting on its
behalf (as determined in the reasonable good faith judgment of the Investor), in addition to any other remedy provided herein or in the other Transaction Documents, the Investor shall have the right to make a public disclosure, in the form of a
press release, public advertisement or otherwise, of such material, non-public information without the prior approval by the Company; provided the Investor shall have first provided notice to the Company that it believes it has received information
that constitutes material, non-public information, the Company shall have at least 24 hours to publicly disclose such material, non-public information prior to any such disclosure by the Investor, and the Company shall have failed to publicly
disclose such material, non-public information within such time period. The Investor shall not have any liability to the Company, any of its Subsidiaries, or any of their respective directors, officers, employees, shareholders or agents, for any
such disclosure. The Company understands and confirms that the Investor shall be relying on the foregoing covenants in effecting transactions in securities of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Purchase Records</U>. The Investor and the Company shall each maintain records showing the remaining Available Amount at any given time
and the dates and Purchase Amounts for each Regular Purchase and Accelerated Purchase or shall use such other method, reasonably satisfactory to the Investor and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Taxes.</U> The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and
delivery of any Common Shares to the Investor made under this Agreement.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Effective Registration Statement; Current
Prospectuses</U>. The Company shall use its reasonable best efforts to keep the Registration Statement effective under the Securities Act (including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
through any necessary renewals), and to keep the Registration Statement and the Prospectuses current and available (including through any necessary renewals) for issuances and sales of all
possible Securities by the Company to the Investor, and for the resale of all of the Securities by the Investor, at all times until the earlier of (i)&nbsp;the date on which the Investor shall have sold all the Securities and no Available Amount
remains under this Agreement and (ii)&nbsp;the earlier of (A)&nbsp;90 days following the Maturity Date and (B)&nbsp;the nine months following the termination of this Agreement in accordance with Section&nbsp;11 hereof (the &#147;<U>Registration
Period</U>&#148;). Without limiting the generality of the foregoing, during the Registration Period, the Company shall (a)&nbsp;take all action necessary to cause the Common Shares to continue to be registered as a class of securities under Sections
12(b) of the Exchange Act and shall not take any action or file any document (whether or not permitted by the Exchange Act) to terminate or suspend such registration, (b)&nbsp;comply with all requirements imposed upon it by Canadian Securities Laws
and the Securities Act, as from time to time in force, and (c)&nbsp;file or furnish on or before their respective due dates all reports and other documents required to be filed or furnished by the Company pursuant to applicable Canadian Securities
Laws or pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act, and shall not take any action or file any document (whether or not permitted by Canadian Securities Laws or the Exchange Act) to terminate or
suspend its reporting and filing obligations under the Exchange Act and Canadian Securities Laws. If during the Registration Period any event occurs as a result of which any Prospectus as then amended or supplemented would include an untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary to amend or supplement or renew the
Canadian Base Prospectus, the Registration Statement or any Prospectus to comply with Canadian Securities Laws or the Securities Act, as applicable, the Company will promptly notify the Investor to suspend use thereof during such period and the
Company will promptly amend or supplement or renew the Canadian Base Prospectus, the Registration Statement or the Prospectuses (at the expense of the Company) so as to correct such statement or omission or effect such compliance. The Company shall
not deliver to the Investor any Regular Purchase Notice or Accelerated Purchase Notice, and the Investor shall not be obligated to purchase any Common Shares under this Agreement, during any such period in which the Investor&#146;s use of the
Canadian Base Prospectus, the Registration Statement or the Prospectuses is so suspended or otherwise unavailable. The Investor shall furnish to the Company such information regarding itself, the Securities held by it and the intended method of
distribution thereof as shall be reasonably requested by the Company in connection with the preparation and filing of any such amendment to or renewal of the Registration Statement, the Canadian Base Prospectus or any Prospectus, and shall otherwise
cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of any such amendment to or renewal of the Registration Statement, the Canadian Base Prospectus or any Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Compliance with Laws</U>. The Company and each of its Subsidiaries shall maintain, or cause to be maintained, all material permits,
licenses and other authorizations required by federal, provincial, state and local law in order to conduct their businesses substantially as described in the Prospectuses, and the Company and each of its Subsidiaries shall conduct their businesses,
or cause their businesses to be conducted, in substantial compliance with such permits, licenses and authorizations and with applicable laws, except where the failure to maintain or be in compliance with such permits, licenses and authorizations
could not reasonably be expected to have a Material Adverse Effect. The Company shall comply with all requirements imposed upon it by Canadian Securities Laws, the Securities Act and the Exchange Act as from time to time in force in connection with
the offer, issuance and sale of the Securities contemplated by the Transaction Documents. Without limiting the generality of the foregoing, neither the Company nor any of its officers, directors or affiliates will take, directly or indirectly, any
action designed or intended to stabilize or manipulate the price of any security of the Company, or which would reasonably be expected to cause or result in, stabilization or manipulation of the price of any security of the Company. The Company will
conduct its affairs in such a manner so as to reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ensure that neither it nor the Subsidiaries will be or become, at any time prior to the termination of this Agreement, an &#147;investment company,&#148; as such term is defined in the Investment
Company Act, assuming no change in the SEC&#146;s current interpretation as to entities that are not considered an investment company. The Company and the Subsidiaries will use their best efforts to comply with all effective applicable provisions of
the Sarbanes-Oxley Act and The Dodd&#150;Frank Wall Street Reform and Consumer Protection Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Stop Orders</U>. The Company shall
advise the Investor promptly (but in no event later than 24 hours) and shall confirm such advice in writing: (i)&nbsp;of the Company&#146;s receipt of notice of any request by the SEC, any Canadian Qualifying Authority, or any other federal,
provincial or state governmental authority for amendment of or a supplement to the Canadian Base Prospectus, the Registration Statement or any Prospectus or for any additional information; (ii)&nbsp;of the Company&#146;s receipt of notice of the
issuance by the SEC, any Canadian Qualifying Authority, or any other federal, provincial or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or prohibiting or suspending the use of the
Canadian Base Prospectus or Canadian Prospectus Supplement, or of the Company&#146;s receipt of any notification of the suspension of qualification of the Securities for offering or sale in any jurisdiction or the initiation or contemplated
initiation of any proceeding for such purpose; and (iii)&nbsp;of the Company becoming aware of the happening of any event, which makes any statement of a material fact made in the Canadian Base Prospectus, the Registration Statement or any
Prospectus untrue or which requires the making of any additions to or changes to the statements then made in the Canadian Base Prospectus, the Registration Statement or any Prospectus in order to state a material fact required by the Securities Act
or Canadian Securities Laws to be stated therein or necessary in order to make the statements then made therein (in the case of any Prospectus, in light of the circumstances under which they were made) not misleading, or of the necessity to amend
the Canadian Base Prospectus, the Registration Statement or any Prospectus to comply with the Securities Act, Canadian Securities Laws or any other law. The Company shall not be required to disclose to the Investor the substance or specific reasons
of any of the events set forth in clauses (i)&nbsp;through (iii)&nbsp;of the immediately preceding sentence, but rather, shall only be required to disclose that the event has occurred. The Company shall not deliver to the Investor any Regular
Purchase Notice or Accelerated Purchase Notice, and the Investor shall not be obligated to purchase any Common Shares under this Agreement and agrees not to resell any Securities covered by the Registration Statement or the Canadian Prospectuses
through the Registration Statement or the Canadian Prospectuses, as applicable, during the continuation or pendency of any of the foregoing events. If at any time the SEC, any Canadian Qualifying Authority, or any other federal, provincial or state
governmental authority shall issue any stop order suspending the effectiveness of the Registration Statement or prohibiting or suspending the use of the Canadian Base Prospectus or Canadian Prospectus Supplement, the Company shall use its reasonable
best efforts to obtain the withdrawal of such order at the earliest possible time. The Company shall furnish to the Investor, without charge, a copy of any correspondence from the SEC or the staff of the SEC, any Canadian Qualifying Authority, or
any other federal, provincial or state governmental authority to the Company or its representatives relating to the Canadian Base Prospectus, the Registration Statement or any Prospectus, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Amendments to Registration Statement; Prospectus Supplements</U>. During the Registration Period, (i)&nbsp;the Company will notify the
Investor promptly of the time when any subsequent amendment to the Canadian Base Prospectus or the Registration Statement, other than documents incorporated by reference, has been filed with any Canadian Qualifying Authority or the SEC, as
applicable, and/or has become effective or where a receipt has been issued therefor or any subsequent supplement to a Prospectus has been filed and of any request by any Canadian Qualifying Authority or the SEC for any amendment or supplement to the
Canadian Base Prospectus, the Registration Statement or any Prospectus or for additional information, (ii)&nbsp;the Company will prepare and file with Canadian Qualifying Authorities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the SEC, promptly upon the Investor&#146;s request, any amendments or supplements to the Canadian Base Prospectus, the Registration Statement or any Prospectus, as applicable, that, in the
Investor&#146;s reasonable opinion, may be necessary or advisable in connection with any acquisition or sale of Securities by the Investor (provided, however, that the failure of the Investor to make such request shall not relieve the Company of any
obligation or liability hereunder, or affect the Investor&#146;s right to rely on the representations and warranties made by the Company in this Agreement); (iii)&nbsp;the Company will not file any amendment or supplement to the Canadian Base
Prospectus, the Registration Statement or any Prospectus, other than documents incorporated by reference, relating to the Investor, the Securities or the transactions contemplated hereby unless (A)&nbsp;the Investor shall have been advised and
afforded the opportunity to review and comment thereon at least two (2)&nbsp;Business Days prior to filing with the SEC or any Canadian Qualifying Authority, as the case may be, (B)&nbsp;the Company shall have given due consideration to any comments
thereon received from the Investor or its counsel, and (C)&nbsp;the Investor has not reasonably objected thereto (provided, however, that the failure of the Investor to make such objection shall not relieve the Company of any obligation or liability
hereunder, or affect the Investor&#146;s right to rely on the representations and warranties made by the Company in this Agreement), and the Company will furnish to the Investor at the time of filing thereof a copy of any document that upon filing
is deemed to be incorporated by reference into the Canadian Base Prospectus, the Registration Statement or any Prospectus, except for those documents available via SEDAR or EDGAR; and (iv)&nbsp;the Company will cause each amendment or supplement to
the Canadian Prospectuses, other than documents incorporated by reference, to be filed with Canadian Qualifying Authorities in accordance with applicable Canadian Securities Laws and will cause each amendment or supplement to the U.S. Prospectuses,
other than documents incorporated by reference, to be filed with the SEC as required pursuant to General Instruction II.L of Form F-10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Prospectus Delivery</U>. The Company will furnish to the Investor and its counsel (at the expense of the Company) copies of the
Canadian Base Prospectus, the Registration Statement, the Form F-X, the Prospectuses (including all documents incorporated by reference therein) and all amendments and supplements to the Canadian Base Prospectus, the Registration Statement or the
Prospectuses that are filed with Canadian Qualifying Authorities or the SEC during the Registration Period (including all documents filed with or furnished to Canadian Qualifying Authorities or the SEC, as applicable, during such period that are
deemed to be incorporated by reference therein), in each case as soon as reasonably practicable and in such quantities as the Investor may from time to time reasonably request and, at the Investor&#146;s request, will also furnish copies of the U.S.
Prospectuses to each U.S. exchange or U.S. market on which sales of the Securities may be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectuses) to the Investor to the extent such
document is available on SEDAR or EDGAR. The Investor shall comply with the prospectus delivery requirements under the Securities Act in connection with any resale of the Securities under the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Use of Proceeds</U>. The Company will use the net proceeds from the offering contemplated hereby as described in the Prospectuses in
the section entitled &#147;Use of Proceeds.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Earnings Statement</U>. The Company will make generally available to its
security holders as soon as practicable, but in any event not later than 15 months after the end of the Company&#146;s current fiscal quarter, an earnings statement covering a 12-month period that satisfies the provisions of Section&nbsp;11(a) and
Rule 158 of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>PFIC Status</U>. For each taxable year in which the Company determines it is a &#147;passive
foreign investment company&#148; as defined in Section&nbsp;1297 of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), the Company will provide to holders of Common Shares that are U.S. taxpayers upon written request, or
post on the Company&#146;s website, the required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information to enable such holders to make a qualified electing fund election under Section&nbsp;1295 of the Code and the Treasury Regulations promulgated thereunder, and will satisfy all
requirements described therein (which, for the avoidance of doubt, shall include providing a PFIC Annual Information Statement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)
<U>Other Transactions</U>. During the term of this Agreement, the Company shall not enter into, announce or recommend to its shareholders any agreement, plan, arrangement or transaction in or of which the terms thereof would restrict, materially
delay, conflict with or impair the ability or right of the Company to perform its obligations under the Transaction Documents, including, without limitation, the obligation of the Company to deliver the Purchase Shares and the Commitment Shares to
the Investor in accordance with the terms of the Transaction Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>No Offer to Sell</U>. Neither the Investor nor the Company
(including its agents and representatives) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities Act), required to be filed with the SEC, that constitutes an offer to sell or
solicitation of an offer to buy Common Shares hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>No Canadian Offers or Sales by Investor</U>. The Investor covenants and
agrees that it shall: (i)&nbsp;offer or sell any Securities that may be issued pursuant to this Agreement only (A)&nbsp;in transactions executed on the Principal Market through a registered broker-dealer located in the United States or
(B)&nbsp;directly to third Persons, none of whom, to the Investor&#146;s knowledge following reasonable inquiry, is a Person resident in Canada; (ii)&nbsp;not offer or sell any Securities that may be issued pursuant to this Agreement on the TSX, any
other Canadian stock exchange or quotation system, or directly to any third Person whom, to the Investor&#146;s knowledge following reasonable inquiry, is a Person resident in Canada; (iii)&nbsp;deliver to the Company, promptly after the issuance of
Securities pursuant to this Agreement, a certificate stating that with respect to any resales of such Securities by the Investor, the Investor shall comply with clauses (i)&nbsp;and (ii)&nbsp;of this Section&nbsp;5(s); and (iv)&nbsp;with respect to
any resale of such Securities by the Investor in any transaction referred to in clause (i)(B) of this Section&nbsp;5(s), the Investor shall include in each confirmation slip delivered by the Investor to the purchaser of such Securities a statement
that it is the Investor&#146;s understanding that such purchaser is not a Person resident in Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Required Filings Relating to
Purchases</U>. The Company agrees to disclose in its quarterly reports, annual information form or annual financial statements / annual report on Form 40-F or 20-F and, if requested by the Investor, in prospectus supplements to be filed from time to
time, the number of Purchase Shares sold to the Investor during the relevant period, the purchase price for such Purchase Shares and the net proceeds received by the Company from such sales. The Company shall not file any prospectus supplement
pursuant to this Section&nbsp;5(t), and shall not file any report containing disclosure relating to such sales of Purchase Shares, unless a copy of such prospectus supplement or disclosure has been submitted to the Investor a reasonable period of
time before the filing and the Investor has not reasonably objected thereto (it being acknowledged and agreed that the Company shall not submit to the Investor any portion of any quarterly reports, annual information form or annual financial
statements / annual report on Form 40-F or 20-F other than the specific disclosure relating to any sales of Purchase Shares). The Company shall also furnish copies of all such prospectus supplements to each exchange or market in the United States on
which sales of the Purchase Shares may be made as may be required by the rules or regulations of such exchange or market, if applicable. For so long as the Common Shares are listed on the TSX, within 10 calendar days after the end of each month
during the term of this Agreement, the Company will, in addition to filing a Form 1 with the TSX, separately e-mail to the TSX a schedule indicating the aggregate number and price of Purchase Shares sold on a daily basis during such month or as the
TSX may otherwise direct, and will provide, upon the request of the TSX, additional monthly reports of daily sales of the Purchase Shares, which schedules and reports shall be submitted to the TSX on a confidential, non-public basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSFER AGENT INSTRUCTIONS. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Commencement Date, (i)&nbsp;the Investor shall pay
to the Company US$1,000,000.77 as full payment for the Initial Purchase Shares via wire transfer of immediately available funds to an account designated by the Company by written notice to the Investor in accordance with this Agreement and
(ii)&nbsp;the Company shall issue to the Transfer Agent (and any subsequent transfer agent) irrevocable instructions, in the form furnished to the Company by the Investor and in the form satisfactory to the Company acting reasonably, to issue the
Purchase Shares and the Commitment Shares in accordance with the terms of this Agreement (the &#147;<U>Irrevocable Transfer Agent Instructions</U>&#148;). All Securities to be issued to or for the benefit of the Investor pursuant to this Agreement
shall be issued as DWAC Shares. The Company warrants to the Investor that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section&nbsp;6 will be given by the Company to the Transfer Agent with respect to the
Securities, and the Securities shall otherwise be freely transferable on the books and records of the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONDITIONS TO THE COMPANY&#146;S RIGHT TO COMMENCE SALES OF COMMON SHARES. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right of
the Company hereunder to commence sales of the Purchase Shares on the Commencement Date is subject to the satisfaction or, where legally permissible, the waiver of each of the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Investor shall have executed this Agreement and delivered the same to the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) No stop order with respect to the Registration Statement shall be pending or threatened by the SEC; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The representations and warranties of the Investor shall be true and correct in all material respects as of the date hereof and as of the
Commencement Date as though made at that time. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONDITIONS TO THE INVESTOR&#146;S OBLIGATION TO PURCHASE COMMON SHARES. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligation
of the Investor to buy Purchase Shares under this Agreement is subject to the satisfaction or, where legally permissible, the waiver of each of the following conditions on or prior to the Commencement Date and, once such conditions have been
initially satisfied, there shall not be any ongoing obligation to satisfy such conditions after the Commencement has occurred: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The
Company shall have executed each of the Transaction Documents and delivered the same to the Investor; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Common Shares shall be
listed or quoted on the Principal Market and conditionally listed on the TSX, subject only to customary listing conditions, trading in the Common Shares shall not have been within the last 365 days suspended by the SEC, the Principal Market or the
TSX, and all Securities to be issued by the Company to the Investor pursuant to this Agreement shall have been approved for listing or quotation on the Principal Market and the TSX in accordance with the applicable rules and regulations of the
Principal Market and the TSX, as applicable, subject only to official notice of issuance and the Exchange Cap and any standard listing conditions for transactions of this nature; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Investor shall have received the opinions of the Company&#146;s U.S. counsel (including
intellectual property counsel) and the Company&#146;s Canadian Counsel, dated as of the Commencement Date, in the form to be agreed upon between the parties hereto and their legal counsel; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The representations and warranties of the Company contained in this Agreement shall be true and correct in all material respects (except
to the extent that any of such representations and warranties are qualified as to materiality, in which case, such representations and warranties shall be true and correct as so qualified) as of the date hereof and as of the Commencement Date as
though made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct in all material respects as of such date) and the Company shall have performed, satisfied and complied in all
material respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement Date. The Investor shall have received a certificate,
executed by the CEO, President or CFO of the Company, dated as of the Commencement Date, to the foregoing effect in the form attached hereto as <B><U>Exhibit A</U></B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Board of Directors of the Company shall have adopted resolutions in connection with this Agreement and the transactions contemplated
hereby which shall be in full force and effect without any amendment or supplement thereto as of the Commencement Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) As of the
Commencement Date, the Company shall have reserved out of its authorized and unissued Common Shares, solely for the purpose of effecting purchases of Purchase Shares hereunder, the Purchase Shares and the Commitment Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Irrevocable Transfer Agent Instructions shall have been delivered to the Company&#146;s Transfer Agent (or any successor transfer
agent) and acknowledged in writing by the Company and the Company&#146;s Transfer Agent (or any successor transfer agent), and the Initial Commitment Shares required to be issued upon the purchase of the Initial Purchase Shares in accordance with
Section&nbsp;5(e) hereof shall have been issued directly to the Investor electronically as DWAC Shares; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Company shall have
delivered to the Investor a certificate of status in respect of the Company issued by the Registrar of Corporations for the Province of Alberta as of the Commencement Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have delivered to the Investor a secretary&#146;s certificate executed by the Secretary of the Company, dated as of the
Commencement Date, in the form attached hereto as <B><U>Exhibit B</U></B>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Registration Statement shall continue to be effective
and no stop order with respect to the Registration Statement shall be pending or threatened by the SEC. The Company shall have a maximum dollar amount certain of Common Shares registered under the Registration Statement which is sufficient to issue
to the Investor not less than (i)&nbsp;the full Available Amount worth of Purchase Shares plus (ii)&nbsp;all of the Commitment Shares. The Current Report and the U.S. Prospectuses each shall have been filed with the SEC, the Canadian Prospectuses
shall have been filed with the Canadian Qualifying Authorities, and the Initial Press Release shall have been issued, in each case as required pursuant to Section&nbsp;5(a), and copies of the Prospectuses shall have been delivered to the Investor in
accordance with Section&nbsp;5(m) hereof. The Prospectuses shall be current and available for issuances and sales of all of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities by the Company to the Investor, and for the resale of all of the Securities by the Investor. Any other prospectus supplements required to have been filed by the Company with the SEC
under the Securities Act or any Canadian Qualifying Authority under Canadian Securities Laws at or prior to the Commencement Date shall have been filed with the SEC or such Canadian Qualifying Authority, as applicable, within the applicable time
periods prescribed for such filings under the Securities Act or Canadian Securities Laws, as applicable. All reports, schedules, registrations, forms, statements, information and other documents required to have been filed by the Company with the
SEC or any Canadian Qualifying Authority at or prior to the Commencement Date pursuant to the reporting requirements of the Exchange Act or Canadian Securities Laws, as applicable, shall have been filed with the SEC or such Canadian Qualifying
Authority, as applicable, within the applicable time periods prescribed for such filings under the Exchange Act or Canadian Securities Laws, as applicable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) No Event of Default has occurred, or any event which, after notice and/or lapse of time, would become an Event of Default has occurred;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) All federal, state, provincial, local and foreign governmental laws, rules and regulations applicable to the transactions
contemplated by the Transaction Documents and necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been
complied with, and all consents, authorizations and orders of, and all filings and registrations with, all federal, state, provincial, local and foreign courts or governmental agencies and all federal, state, provincial, local and foreign regulatory
or self-regulatory agencies necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained or made,
including, without limitation, in each case those required under Canadian Securities Laws, the Securities Act, the Exchange Act, applicable U.S. state securities or &#147;Blue Sky&#148; laws or applicable rules and regulations of the Principal
Market and the TSX, or otherwise required by the Canadian Qualifying Authorities, the SEC, the Principal Market, the TSX or any U.S. state or Canadian provincial securities regulators; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed by
any federal, state, provincial, local or foreign court or governmental authority of competent jurisdiction which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated by the Transaction
Documents; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) No action, suit or proceeding before any federal, state, provincial, local or foreign arbitrator or any court or
governmental authority of competent jurisdiction shall have been commenced or threatened, and no inquiry or investigation by any federal, state, provincial, local or foreign governmental authority of competent jurisdiction shall have been commenced
or threatened, against the Company, or any of the officers, directors or affiliates of the Company, seeking to restrain, prevent or change the transactions contemplated by the Transaction Documents, or seeking material damages in connection with
such transactions; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company shall have furnished to the Investor satisfactory evidence of its due and valid authorization of
CT Corporation System. as its agent to receive service of process in the United States pursuant to Section&nbsp;12(a) hereof, and satisfactory evidence from CT Corporation System accepting its appointment as such agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INDEMNIFICATION. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Investor&#146;s execution and delivery of the
Transaction Documents and acquiring the Securities hereunder and in addition to all of the Company&#146;s other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold harmless the Investor and all of its
affiliates, shareholders, officers, directors, employees and direct or indirect investors and any of the foregoing Person&#146;s agents or other representatives (including, without limitation, those retained in connection with the transactions
contemplated by this Agreement) (collectively, the &#147;<U>Indemnitees</U>&#148;) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith
(irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys&#146; fees and disbursements but excluding loss of profits (the &#147;<U>Indemnified
Liabilities</U>&#148;), incurred by any Indemnitee as a result of, or arising out of, or relating to: (a)&nbsp;any misrepresentation or breach of any representation or warranty made by the Company in the Transaction Documents or any other
certificate, instrument or document contemplated hereby or thereby, (b)&nbsp;any breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or any other certificate, instrument or document contemplated
hereby or thereby, (c)&nbsp;any cause of action, suit or claim brought or made against such Indemnitee and arising out of or resulting from the execution, delivery, performance or enforcement of the Transaction Documents or any other certificate,
instrument or document contemplated hereby or thereby, (d)&nbsp;any violation of the Securities Act, the Exchange Act, U.S. state securities or &#147;Blue Sky&#148; laws or Canadian Securities Laws, or the rules and regulations of the Principal
Market or the TSX in connection with the transactions contemplated by the Transaction Documents by the Company or any of its Subsidiaries, affiliates, officers, directors or employees, (e)&nbsp;any untrue statement or alleged untrue statement of a
material fact contained in the Canadian Base Prospectus, the Registration Statement or any Prospectus or any amendment or supplement to the Canadian Base Prospectus, the Registration Statement or any Prospectus or in any free writing prospectus or
in any application or other document executed by or on behalf of the Company or based on written information furnished by or on behalf of the Company filed in any jurisdiction in order to qualify the Common Shares under the securities laws thereof
or filed with any Canadian Qualifying Authority or the SEC, (f)&nbsp;the omission or alleged omission to state in any such document a material fact required to be stated in it or necessary to make the statements in it not misleading, or (g)&nbsp;the
failure of the Canadian Base Prospectus or the Canadian Prospectuses or any amendment or supplement to the Canadian Base Prospectus or the Canadian Prospectuses to contain full, true and plain disclosure of all material facts relating to the
Securities and to the Company; provided, however, that (I)&nbsp;the indemnity contained in clause (c)&nbsp;of this Section&nbsp;9 shall not apply to any Indemnified Liabilities which directly and primarily result from the fraud, gross negligence or
willful misconduct of an Indemnitee, (II) the indemnity contained in clauses (d), (e), (f)&nbsp;and (g)&nbsp;of this Section&nbsp;9 shall not apply to any Indemnified Liabilities to the extent, but only to the extent, arising out of or based upon
any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Investor expressly for use in any Prospectus (it being
hereby acknowledged and agreed that the written information set forth on <B><U>Exhibit C</U></B> attached hereto is the only written information furnished to the Company by or on behalf of the Investor expressly for use in any Prospectus), if the
Prospectus was timely made available by the Company to the Investor pursuant to Section&nbsp;5(m), (III) the indemnity contained in clauses (d), (e), (f)&nbsp;and (g)&nbsp;of this Section&nbsp;9 shall not inure to the benefit of the Investor to the
extent such Indemnified Liabilities are based on a failure of the Investor to deliver or to cause to be delivered any Prospectus made available by the Company, if such Prospectus was timely made available by the Company pursuant to
Section&nbsp;5(m), and if delivery of the Prospectus would have cured the defect giving rise to such Indemnified Liabilities, and (IV) the indemnity in this Section&nbsp;9 shall not apply to amounts paid in settlement of any claim if such settlement
is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company
shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
law. Payment under this indemnification shall be made within thirty (30)&nbsp;days from the date Investor makes written request for it. A certificate containing reasonable detail as to the amount
of such indemnification submitted to the Company by Investor shall be conclusive evidence, absent manifest error, of the amount due from the Company to Investor. If any action shall be brought against any Indemnitee in respect of which indemnity may
be sought pursuant to this Agreement, such Indemnitee shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Indemnitee. Any
Indemnitee shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnitee, except to the extent that (i)&nbsp;the
employment thereof has been specifically authorized by the Company in writing, (ii)&nbsp;the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii)&nbsp;in such action there is, in the reasonable
opinion of such separate counsel, a material conflict on any material issue between the position of the Company and the position of such Indemnitee, in which case the Company shall be responsible for the reasonable fees and expenses of no more than
one such separate counsel. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EVENTS OF DEFAULT. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#147;<U>Event of Default</U>&#148; shall be deemed to have
occurred at any time as any of the following events occurs: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the effectiveness of the Registration Statement registering the
Securities lapses for any reason (including, without limitation, the issuance of a stop order or similar order) or any of the Canadian Base Prospectus, the Registration Statement or any Prospectus is unavailable for the sale by the Company to the
Investor (or the resale by the Investor) of any or all of the Securities to be issued to the Investor under the Transaction Documents (including, without limitation, as a result of any failure of the Company to satisfy all of the requirements for
the use of a registration statement on Form F-10 pursuant to the Securities Act for the offering and sale of the Securities contemplated by this Agreement), and such lapse or unavailability continues for a period of ten (10)&nbsp;consecutive
Business Days or for more than an aggregate of thirty (30)&nbsp;Business Days in any 365-day period; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the suspension of the Common
Shares from trading or the failure of the Common Shares to be listed on the Principal Market for a period of one (1)&nbsp;Business Day, provided that the Company may not direct the Investor to purchase any Common Shares during any such suspension;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the delisting of the Common Shares from The NASDAQ Capital Market, provided, however, that the Common Shares are not immediately
thereafter trading on the New York Stock Exchange, The NASDAQ Global Market, The NASDAQ Global Select Market, the NYSE MKT, the NYSE Arca, the OTC Bulletin Board or OTC Markets (or nationally recognized successor to any of the foregoing); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the failure for any reason by the Transfer Agent to issue Purchase Shares or Additional Commitment Shares to the Investor within three
(3)&nbsp;Business Days after the applicable payment therefor; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the Company breaches any representation, warranty, covenant or other
term or condition under any Transaction Document if such breach could have a Material Adverse Effect and except, in the case of a breach of a covenant which is reasonably curable, only if such breach continues for a period of at least five
(5)&nbsp;Business Days after the Company receives notice of such breach; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) if any Person commences a proceeding against the Company pursuant to or within the meaning of
any Bankruptcy Law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) if the Company, pursuant to or within the meaning of any Bankruptcy Law, (i)&nbsp;commences a voluntary case,
(ii)&nbsp;consents to the entry of an order for relief against it in an involuntary case, (iii)&nbsp;consents to the appointment of a Custodian of it or for all or substantially all of its property, or (iv)&nbsp;makes a general assignment for the
benefit of its creditors or is generally unable to pay its debts as the same become due; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) a court of competent jurisdiction enters an
order or decree under any Bankruptcy Law that (i)&nbsp;is for relief against the Company in an involuntary case, (ii)&nbsp;appoints a Custodian of the Company or for all or substantially all of its property, or (iii)&nbsp;orders the liquidation of
the Company or any Subsidiary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) if at any time the Company is not eligible to transfer its Common Shares electronically as DWAC
Shares; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) if at any time after the Commencement Date, the Exchange Cap is reached (to the extent the Exchange Cap is applicable
pursuant to Section&nbsp;2(e) hereof) and the Company&#146;s shareholders have not approved the transactions contemplated by this Agreement in accordance with the applicable rules and regulations of The NASDAQ Stock Market, any other Principal
Market on which the Common Shares may be listed or quoted after the date of this Agreement, and the constating documents of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to
any other rights and remedies under applicable law and this Agreement, so long as an Event of Default has occurred and is continuing, or if any event which, after notice and/or lapse of time, would become an Event of Default, has occurred and is
continuing, or so long as the Closing Sale Price is below the Floor Price, the Company shall not deliver to the Investor any Regular Purchase Notice or Accelerated Purchase Notice, and the Investor shall not purchase any Common Shares under this
Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TERMINATION </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement may be terminated only as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding
against the Company, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors (any of which would be an Event of Default as described in
Sections 10(f), 10(g) and 10(h) hereof), this Agreement shall automatically terminate without any liability or payment to the Company (except as set forth below) without further action or notice by any Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that the Commencement shall not have occurred on or before March&nbsp;15, 2014, due to the failure to satisfy the conditions
set forth in Sections 7 and 8 above with respect to the Commencement, either the Company or the Investor shall have the option to terminate this Agreement at the close of business on such date or thereafter without liability of any party to any
other party (except as set forth below); provided, however, that the right to terminate this Agreement under this Section&nbsp;11(b) shall not be available to any party if such party is then in breach of any covenant or agreement contained in this
Agreement or any representation or warranty of such party contained in this Agreement fails to be true and correct such that the conditions set forth in Section&nbsp;7(c) or Section&nbsp;8(d), as applicable, could not then be satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) At any time after the Commencement Date, the Company shall have the option to terminate this
Agreement for any reason or for no reason by delivering notice (a &#147;<U>Company Termination Notice</U>&#148;) to the Investor electing to terminate this Agreement without any liability whatsoever of any party to any other party under this
Agreement (except as set forth below in this Section&nbsp;11). The Company Termination Notice shall not be effective until one (1)&nbsp;Business Day after it has been received by the Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) This Agreement shall automatically terminate on the date that the Company sells and the Investor purchases the full Available Amount as
provided herein, without any action or notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement (except as set forth below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If for any reason or for no reason the full Available Amount has not been purchased in accordance with Section&nbsp;2 of this Agreement by
the Maturity Date, this Agreement shall automatically terminate on the Maturity Date, without any action or notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement (except as set
forth below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as set forth in Sections 11(a) (in respect of an Event of Default under Sections 10(f), 10(g) and 10(h)), 11(d) and 11(e), any
termination of this Agreement pursuant to this Section&nbsp;11 shall be effected by written notice from the Company to the Investor, or the Investor to the Company, as the case may be, setting forth the basis for the termination hereof. The
representations and warranties and covenants of the Company and the Investor contained in Sections 3, 4, 5, and 6 hereof, the indemnification provisions set forth in Section&nbsp;9 hereof and the agreements and covenants set forth in Sections 10, 11
and 12, shall survive the Commencement and any termination of this Agreement. No termination of this Agreement shall (i)&nbsp;affect the Company&#146;s or the Investor&#146;s rights or obligations under this Agreement with respect to pending Regular
Purchases and Accelerated Purchases and the Company and the Investor shall complete their respective obligations with respect to any pending Regular Purchases and Accelerated Purchases under this Agreement or (ii)&nbsp;be deemed to release the
Company or the Investor from any liability for intentional misrepresentation or willful breach of any of the Transaction Documents. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MISCELLANEOUS. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Governing Law; Jurisdiction; Jury Trial</U>. The construction,
validity, enforcement and interpretation of this Agreement and the other Transaction Documents shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether
of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, borough of Manhattan, for the adjudication of any dispute hereunder or under the other Transaction Documents or in connection herewith or therewith, or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient
forum or that the venue of such suit, action or proceeding is improper. By the execution and delivery of this Agreement, the Company acknowledges that it has, by separate written instrument, irrevocably designated and appointed CT Corporation
System, at 111 Eighth Avenue, New York, NY 10011 (together with any successor, the &#147;<U>Agent for Service</U>&#148;) as its authorized agent upon which process may be served in any suit or proceeding arising out of or relating to this Agreement
that may be instituted in any state or federal court sitting in the City of New York, borough of Manhattan, or brought under federal or state securities laws, and acknowledges that the Agent for Service has accepted such designation. The Company
further agrees to take any and all action, including the execution and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-35- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
filing of any and all such documents and instruments, as may be necessary to continue such designation and appointment of the Agent for Service in full force and effect so long as any of the
Common Shares shall be outstanding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof (certified or registered mail, return receipt
requested) to such party at the address in effect for notices to it under this Agreement (or, in the case of the Company, to the Agent for Service) and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. <B>EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Counterparts</U>. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the
same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature or signature delivered by e-mail in a &#147;.pdf&#148; format data file shall be
considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Headings</U>. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Severability</U>. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction,
such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Entire Agreement; Amendment</U>. This Agreement supersedes all other prior oral or written agreements between the Investor, the
Company, their affiliates and Persons acting on their behalf with respect to the subject matter hereof, and this Agreement, the other Transaction Documents and the instruments referenced herein contain the entire understanding of the parties with
respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Investor makes any representation, warranty, covenant or undertaking with respect to such matters. The Company
acknowledges and agrees that is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly set forth in the Transaction Documents. No provision of this Agreement may be amended other than
by a written instrument signed by both parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-36- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Notices</U>. Any notices, consents or other communications required or permitted to be
given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i)&nbsp;upon receipt when delivered personally; (ii)&nbsp;upon receipt when sent by facsimile or email (provided confirmation of transmission is
mechanically or electronically generated and kept on file by the sending party); or (iii)&nbsp;one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same.
The addresses for such communications shall be: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">If to the Company:</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Oncolytics Biotech Inc.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">210, 1167 Kensington Crescent NW</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Calgary, Alberta, Canada T2N 1X7</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(403) 670-7658</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(403) 283-0858</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">E-mail:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">klook@oncolytics.ca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Kirk Look, Chief Financial Officer</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">With a copy to (which shall not constitute notice or service of process):</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Norton Rose Fulbright Canada LLP</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">400 3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> Avenue SW, Suite 3700</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Calgary, Alberta Canada T2P 4H2</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(403) 355-3836</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(403) 355-3551</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">E-mail:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">matthew.hall@nortonrosefulbright.com</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Matthew J. Hall, Esq.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">and</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Dorsey &amp; Whitney LLP</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">1400 Wewatta Street, Suite 400</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Denver, Colorado 80202</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(303) 352-1133</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(303) 629-3450</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">E-mail:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">brenkert.jason@dorsey.com</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Jason K. Brenkert, Esq.</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">If to the Investor:</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Lincoln Park Capital Fund, LLC</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">440 North Wells, Suite 410</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Chicago, IL 60654</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">312-822-9300</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">312-822-9301</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">E-mail:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">jscheinfeld@lpcfunds.com/jcope@lpcfunds.com</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Josh Scheinfeld/Jonathan Cope</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">With a copy to (which shall not constitute notice or service of process):</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Greenberg Traurig, LLP</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">The MetLife Building</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">200 Park Avenue</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">New York, NY 10166</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(212) 801-9200</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(212) 801-6400</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">E-mail:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">marsicoa@gtlaw.com</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Anthony J. Marsico, Esq.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">and</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-37- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Baker &amp; McKenzie LLP</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Brookfield Place</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Bay/Wellington Tower</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">181 Bay Street, Suite 2100</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Toronto, Ontario, Canada M5J 2T3</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(416) 865-6875</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(416) 863-6275</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">E-mail:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">sonia.yung@bakermckenzie.com</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Sonia M. Yung, Esq.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or at such other address and/or facsimile number and/or to the attention of such other Person as the recipient party has
specified by written notice given to each other party three (3)&nbsp;Business Days prior to the effectiveness of such change. Written confirmation of receipt (A)&nbsp;given by the recipient of such notice, consent or other communication,
(B)&nbsp;mechanically or electronically generated by the sender&#146;s facsimile machine or email account containing the time, date, and recipient facsimile number or email address, as applicable, and an image of the first page of such transmission
or (C)&nbsp;provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery service in accordance with clause (i),
(ii)&nbsp;or (iii)&nbsp;above, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the
benefit of the parties and their respective successors and assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor, including by merger or consolidation. The
Investor may not assign its rights or obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>No Third Party Beneficiaries</U>. This Agreement is
intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Publicity</U>. The Company shall use commercially reasonable efforts to afford the Investor and its counsel with the opportunity to
review and comment upon, shall consult with the Investor and its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor or its counsel on, any press release by or on behalf of the Company
relating to the Investor, its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby, not less than 24 hours prior to the issuance, filing or public disclosure thereof. The Investor shall use
commercially reasonable efforts to afford the Company and its counsel with the opportunity to review and comment upon, shall consult with the Company and its counsel on the form and substance of, and shall give due consideration to all such comments
from the Company or its counsel on, any press release by or on behalf of the Investor relating to the Company, the Investor&#146;s purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby, not less than
24 hours prior to the issuance, filing or public disclosure thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Further Assurances</U>. Each party shall do and perform, or
cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>No Financial Advisor,
Placement Agent, Broker or Finder</U>. The Company represents and warrants to the Investor that, except as disclosed in <U>Schedule 4(x)</U>, it has not engaged any financial advisor, placement agent, broker or finder in connection with the
transactions contemplated hereby. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-38- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investor represents and warrants to the Company that it has not engaged any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The
Company shall not be responsible for the payment of any fees or commissions, if any, of any broker-dealer engaged by the Investor after the date of this Agreement in connection with any resale of the Securities by the Investor. The Company shall be
responsible for the payment of any fees or commissions, if any, of any financial advisor, placement agent, broker or finder engaged by the Company relating to or arising out of the transactions contemplated hereby; provided, however, that the
Company shall not be responsible for the payment of any fees or commissions, if any, of any financial advisor, placement agent, broker or finder engaged by the Investor in connection with the transactions contemplated hereby. The Company shall pay,
and hold the Investor harmless against, any liability, loss or expense (including, without limitation, attorneys&#146; fees and out of pocket expenses) arising in connection with any claim for fees or commissions of any financial advisor, placement
agent, broker or finder engaged by the Company in connection with the transactions contemplated hereby. The Investor shall pay, and hold the Company harmless against, any liability, loss or expense (including, without limitation, attorneys&#146;
fees and out of pocket expenses) arising in connection with any claim for fees or commissions of any financial advisor, placement agent, broker or finder engaged by the Investor in connection with the transactions contemplated hereby, including any
resale of the Securities by the Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>No Strict Construction</U>. The language used in this Agreement will be deemed to be the
language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)
<U>Remedies, Other Obligations, Breaches and Injunctive Relief</U>. The parties remedies provided in this Agreement, including, without limitation, the Investor&#146;s remedies provided in Section&nbsp;9, shall be cumulative and in addition to all
other remedies available to the parties under this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief), no remedy of any party contained herein shall be deemed a waiver of compliance with the
provisions giving rise to such remedy and nothing herein shall limit any party&#146;s right to pursue actual damages for any failure by the other party to comply with the terms of this Agreement. The parties acknowledge that a breach by any party of
its obligations hereunder will cause irreparable harm to the non-breaching party and that the remedy at law for any such breach may be inadequate. The parties therefore agree that, in the event of any such breach or threatened breach, the
non-breaching party shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Enforcement Costs</U>. If: (i)&nbsp;this Agreement is placed by the Investor in the hands of an attorney for enforcement or is enforced
by the Investor through any legal proceeding; (ii)&nbsp;an attorney is retained to represent the Investor in any bankruptcy, reorganization, receivership or other proceedings affecting creditors&#146; rights and involving a claim under this
Agreement; or (iii)&nbsp;an attorney is retained to represent the Investor in any other proceedings whatsoever in connection with this Agreement, then the Company shall pay to the Investor, as incurred by the Investor, all reasonable costs and
expenses including attorneys&#146; fees incurred in connection therewith if the Investor is the prevailing party in any such proceeding, in addition to all other amounts due hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Waivers</U>. No provision of this Agreement may be waived other than in a written instrument signed by the party against whom
enforcement of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or
further exercise thereof or of any other right, power or privilege. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-39- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Adjustments for Share Splits</U>. The parties acknowledge and agree that all share-related
numbers contained in this Agreement shall be adjusted to take into account any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction effected with respect to the Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-40- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Investor and the Company have caused this Agreement to be duly
executed as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>THE COMPANY:</U></B></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ONCOLYTICS BIOTECH INC.</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kirk Look</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Kirk Look</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTOR:</U></B></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LINCOLN PARK CAPITAL FUND, LLC</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BY: LINCOLN PARK CAPITAL, LLC</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BY: ALEX NOAH INVESTORS, INC.</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Cope</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Jonathan Cope</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-41- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><U>SCHEDULES</U></B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;4(x)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Agent Fees</TD></TR>
<TR>
<TD HEIGHT="32" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><U>EXHIBITS</U></B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit A</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Form of Officer&#146;s Certificate</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit B</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Form of Secretary&#146;s Certificate</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit C</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Information About Investor Furnished to the Company</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DISCLOSURE SCHEDULES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule 4(x) &#150; Agent Fees </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF OFFICER&#146;S CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Officer&#146;s Certificate (&#147;<B>Certificate</B>&#148;) is being delivered pursuant to Section&nbsp;8(d) of that certain Purchase
Agreement dated as of February&nbsp;27, 2014, (&#147;<B>Purchase Agreement</B>&#148;), by and between<B> ONCOLYTICS BIOTECH INC.</B>, a company incorporated under the <I>Business Corporations Act (Alberta)</I> (the &#147;<B>Company</B>&#148;), and
<B>LINCOLN PARK CAPITAL FUND, LLC </B>(the &#147;<B>Investor</B>&#148;). Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The undersigned, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the Company, hereby certifies as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I am the
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the Company and make the statements contained in this Certificate; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The representations and warranties of the Company contained in the Purchase Agreement are true and correct in all material
respects (except to the extent that any of such representations and warranties are qualified as to materiality in the Purchase Agreement, in which case, such representations and warranties are true and correct in all material respects as so
qualified) as of the date of the Purchase Agreement and as of the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date, in which case such representations and warranties are true
and correct in all material respects as of such date); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The Company has performed, satisfied and complied in all
material respects with covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement Date, to the extent not otherwise waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any
Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able
to pay its debts as they become due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, I have hereunder signed my name on this &nbsp;&nbsp;&nbsp;&nbsp; day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned as Secretary of <B>ONCOLYTICS BIOTECH INC.</B>, a company incorporated under the
<I>Business Corporations Act (Alberta)</I>, hereby certifies that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is the duly elected, appointed, qualified and acting
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and that the signature appearing above is his genuine signature. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Secretary</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF SECRETARY&#146;S CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Secretary&#146;s Certificate (&#147;Certificate&#148;) is being delivered pursuant to Section&nbsp;8(j) of that certain Purchase
Agreement dated as of February&nbsp;27, 2014 (the &#147;Purchase Agreement&#148;), by and between <B>ONCOLYTICS BIOTECH INC.</B>, a company incorporated under the <I>Business Corporations Act (Alberta)</I> (the &#147;Company&#148;) and <B>LINCOLN
PARK CAPITAL FUND, LLC</B> (the &#147;Investor&#148;). Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
Secretary of the Company, hereby certifies as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I am the Secretary of the Company and make the statements
contained in this Secretary&#146;s Certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Attached hereto as <U>Exhibit A</U> are true, correct and complete
copies of the Company&#146;s constating documents, as amended through the date hereof, and no action has been taken by the Company, its directors, officers or shareholders, in contemplation of the filing of any further amendment relating to or
affecting the constating documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Attached hereto as <U>Exhibit B</U> are true, correct and complete copies of the
resolutions either duly adopted by the Board of Directors of the Company on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, at which a quorum was present and acting
throughout, or executed by all directors in accordance with the <I>Business Corporations Act (Alberta)</I>. Such resolutions have not been amended, modified or rescinded and remain in full force and effect and such resolutions are the only
resolutions adopted by the Company&#146;s Board of Directors, or any committee thereof, or the shareholders of the Company relating to or affecting (i)&nbsp;the entering into and performance of the Purchase Agreement, or the issuance, offering and
sale of the Purchase Shares and the Commitment Shares and (ii)&nbsp;and the performance of the Company of its obligation under the Transaction Documents as contemplated therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. As of the date hereof, the authorized, issued and reserved capital stock of the Company is as set forth on <U>Exhibit C</U>
hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, I have hereunder signed my name on this &nbsp;&nbsp;&nbsp;&nbsp; day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned as
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of <B>ONCOLYTICS BIOTECH INC.</B>, a company incorporated under the <I>Business Corporations Act (Alberta)</I>, hereby certifies
that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is the duly elected, appointed, qualified and acting Secretary of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and that the signature appearing above is his genuine signature. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Information About The Investor Furnished To The Company By The Investor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expressly For Use In Connection With Prospectuses </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information With Respect to Lincoln Park Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the date of the Purchase Agreement, Lincoln Park Capital Fund, LLC, beneficially owned no Common Shares. Josh Scheinfeld
and Jonathan Cope, the Managing Members of Lincoln Park Capital, LLC, the manager of Lincoln Park Capital Fund, LLC, are deemed to be beneficial owners of all of the Common Shares owned by Lincoln Park Capital Fund, LLC. Messrs. Cope and Scheinfeld
have shared voting and investment power over the shares being offered under the prospectus supplement filed with the SEC in connection with the transactions contemplated under the Purchase Agreement. Lincoln Park Capital, LLC is not a licensed
broker dealer or an affiliate of a licensed broker dealer. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF COMPANY U.S. COUNSEL OPINIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used herein but not defined herein, have the meaning set forth in the Purchase Agreement. Based on the foregoing, and
subject to the assumptions, exceptions and qualifications set forth herein, we are of the opinion that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Registration Statement has
become effective under the Securities Act; the Form F-X was filed with the SEC prior to the effectiveness of the Registration Statement; the filing of the U.S. Base Prospectus and the prospectus supplement thereto filed with the SEC on the date
hereof (such prospectus supplement, together with the U.S. Base Prospectus, the &#147;U.S. Prospectus&#148;) has been made in the manner and within the time period required by General Instruction II.L of Form F-10; to our knowledge, no stop order
suspending the effectiveness of the Registration Statement or any notice objecting to its use has been issued, no proceedings for that purpose have been instituted or threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The Registration Statement, at the time it became effective, and the U.S. Prospectus, as of the date of its filing with the SEC and as of
the date hereof (in each case, other than the financial statements and other financial information contained therein, as to which we express no opinion), appear on their face to be appropriately responsive in all material respects to the applicable
requirements of the Securities Act and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The Form F-X, as of the date of its filing
with the SEC, appears on its face to be appropriately responsive in all material respects to the applicable requirements of the Securities Act and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. [<FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#151;</FONT>] Common Shares to be issued and sold by the Company pursuant to the Purchase
Agreement are duly listed, and admitted and authorized for trading, subject to official notice of issuance, on The NASDAQ Stock Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The statements included in the U.S. Prospectus under the heading &#147;Certain U.S. Federal Income Tax Considerations&#148; fairly
summarize in all material respects the matters therein described, subject to the qualifications contained therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. The statements
included in the U.S. Prospectus under the heading &#147;Plan of Distribution&#148;, in so far as such statements purport to summarize certain provisions of the Purchase Agreement, fairly summarize such provisions in all material respects, subject to
the qualifications contained therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. Assuming due authorization, execution and delivery of the Purchase Agreement under the laws of
the Province of Alberta and the federal laws of Canada applicable therein, the Purchase Agreement (to the extent that execution and delivery are governed by the laws of the State of New York) has been duly executed and delivered by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. Under the laws of the State of New York relating to submission of personal jurisdiction, the Company has, pursuant to Section&nbsp;12(a) of
the Purchase Agreement, validly (i)&nbsp;submitted to the non-exclusive jurisdiction of any state and federal courts sitting in the City of New York, borough of Manhattan, in any action based on or under the Purchase Agreement and
(ii)&nbsp;appointed CT Corporation System as its authorized agent for the purposes described in Section&nbsp;12(a) of the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. The Company is not and, after giving effect to the offering and sale of the Common Shares offered and sold pursuant to the Purchase
Agreement and the application of the proceeds thereof as described in the U.S. Prospectus, will not be required to register as an &#147;investment company&#148; as defined in the Investment Company Act. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. No consent, approval, authorization, filing with or order of any U.S. federal or State of New
York court or governmental agency or body is required in connection with the completion by the Company of the transactions contemplated by the Purchase Agreement, except such as have been obtained under the Securities Act and such as may be required
under the blue sky laws of any jurisdiction, the rules of The NASDAQ Stock Market or the rules of FINRA in connection with the distribution of the Common Shares by the Investor in the manner contemplated in the Purchase Agreement and the U.S.
Prospectus and such other approvals as have been obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. Neither the issue and sale of the Common Shares nor the consummation of
any other of the transactions contemplated by the Purchase Agreement nor the fulfillment of the terms of the Purchase Agreement will conflict with, result in a breach or violation of, or imposition of any lien, charge or encumbrance upon any
property or assets of the Company pursuant to&nbsp;any U.S. statute, law, rule, regulation, judgment, order or decree applicable to the Company of any U.S. court, regulatory body, administrative agency, governmental body, arbitrator or other
authority having jurisdiction over the Company or any of its properties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. To our knowledge, no holders of securities of the Company
have rights to the registration of such securities under the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering such opinion, we may rely as to matters
of fact, to the extent we deem proper, on certificates of responsible officers of the Company and public officials. In addition to rendering the opinions set forth above, we shall also include a statement to the effect that we have participated in
the preparation of the Registration Statement and the U.S. Prospectus and in conferences with officers and other representatives of the Company, Canadian counsel for the Company, representatives of the independent accountants for the Company,
counsel for the Investor and representatives of the Investor at which the contents of the Registration Statement and the U.S. Prospectus and related matters were discussed and although we have not independently verified, and (except as to those
matters and to the extent set forth in paragraphs 5 and 6 of our opinion to you dated the date hereof) we are not passing upon and do not assume any responsibility for, the factual accuracy, completeness or fairness of the statements contained in
the Registration Statement and the U.S. Prospectus, on the basis of such participation, no facts have come to our attention which have caused us to believe that (i)&nbsp;the Registration Statement, at the time such Registration Statement became
effective and as of the date hereof, contained or contains any untrue statement of a material fact or omitted or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;the
U.S. Prospectus, as of the date of the U.S. Prospectus and as of the date hereof, included or includes an untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading (in each case, other than (i)&nbsp;the financial statements and other financial or statistical information, and (ii)&nbsp;the information about or derived from patents,
trademarks, licenses and other intellectual property included or incorporated by reference into the U.S. Prospectus, as to which we express no belief). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF IP COUNSEL OPINIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company and its subsidiaries have issued patents and filed patent applications listed in Schedule A and B attached hereto relating to
the intellectual property referenced in the relevant sections of the Registration Statement and U.S. Prospectuses (the &#147;Documents&#148;), which relate to the Company&#146;s business and about which information is publicly available, in the
jurisdictions identified in Schedules A and B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) On the basis of conferences with officers and other representatives of the Company
and on our examination of the sections of the Documents specified above, but without independent review or verification and without assuming responsibility for the accuracy, completeness or fairness of the statements contained in those sections of
the Documents, as of such Documents&#146; respective dates and at the Commencement Date, nothing has come to our attention that causes us to believe that the statements in the above-identified sections of the Documents (excluding financial data and
statistics), insofar as such statements pertain to intellectual property matters, contain an untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading, and nothing has come to our attention that caused us to believe that the U.S. Prospectuses, as of their dates and as of the date and time of delivery of this letter, with respect to the above-identified sections of
the Documents (excluding financial data and statistics), insofar as such statements pertain to intellectual property matters contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) To our knowledge, there are no actions, suits, claims or
proceedings that have been asserted in a court against the Company or its subsidiaries or threatened against the Company or its subsidiaries alleging infringement of the intellectual property rights of any third party with respect to the
intellectual property as specified in the relevant sections of the Documents or as listed in Schedules A and B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) To our knowledge,
each named inventor of the patents and patent applications listed in Schedule A and B has executed an assignment to the Company of all his or her rights in respect of such patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) To our knowledge, the Company and its subsidiaries own or possess valid rights to use the intellectual property listed in Schedules A and
B, and each such patent and patent application is subsisting in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) To our knowledge, there are no pending or
threatened actions, suits, proceedings, investigations or claims by others challenging the rights of the Company or any of its subsidiaries or, if the intellectual property is licensed to the Company or any of its subsidiaries, in respect of any
third party licensor, with respect to intellectual property as specified in the relevant sections of the Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) To our
knowledge, the Company and its subsidiaries have not received and, to the extent any intellectual property is licensed to the Company or any of its subsidiaries, no third party licensor has received any notice of infringement of or conflict with any
rights of others with respect to intellectual property as specified in the relevant sections of the Documents. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF COMPANY CANADIAN COUNSEL OPINIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used herein but not defined herein, have the meaning set forth in the Purchase Agreement. Based on the foregoing, and
subject to the assumptions and qualifications set forth herein, we are of the opinion that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Company has been continued and is
existing as a corporation in good standing under the laws of the Province of Alberta, with all necessary corporate power and authority to own or lease, as the case may be, and to operate its properties and conduct its business as described in the
Canadian Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The Company has all necessary corporate power and capacity to execute and deliver the Purchase Agreement and
perform its obligations thereunder and to issue the Commitment Shares and issue and sell the Purchase Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;The Company&#146;s
authorized capital is as set forth in the Canadian Prospectus; the Commitment Shares have been duly and validly authorized, and, when issued and delivered to the Investor pursuant to the Purchase Agreement, will be fully paid and non-assessable; the
Purchase Shares have been duly and validly authorized, and, when issued and delivered to and paid for by the Investor pursuant to the Purchase Agreement, will be fully paid and non-assessable; subject only to the standard listing conditions, the
Commitment Shares and the Purchase Shares have been conditionally listed or approved for listing on the TSX; the form and terms of the certificates representing the Commitment Shares and the Purchase Shares have been approved by the directors of the
Company and comply in all material respects with the requirements of the <I>Business Corporations Act (Alberta)</I>, the articles and by-laws of the Company and the rules of the TSX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;To the knowledge of such counsel, there is no pending or threatened action, suit or proceeding by or before any court or governmental
agency, authority or body or any arbitrator in the Province of Alberta involving the Company or its property, of a character required to be disclosed in the Canadian Prospectus which is not adequately disclosed therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;The statements included in the Canadian Prospectus under the headings &#147;Canadian Federal Income Tax Considerations&#148; and
&#147;Statutory Rights of Withdrawal and Rescission&#148; and in the Registration Statement under &#147;Part II &#150; Information not Required to be Delivered to Offerees or Purchasers &#150; Indemnification of Directors and Officers&#148;, insofar
as such statements constitute a description of the laws or regulations applicable in the Province of Alberta or the federal laws of Canada applicable therein or summaries of legal matters under such laws or regulations, or legal conclusions with
respect thereto, fairly summarize in all material respects the matters therein described. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;A Receipt has been obtained in respect
of the Canadian Base Prospectus from the Reviewing Authority on behalf of itself and the other Qualifying Authorities; to the knowledge of such counsel, no order suspending the distribution of the Common Shares has been issued by any Canadian
Qualifying Authority; and the Canadian Base Prospectus and the Canadian Prospectus Supplement (other than financial statements or other financial information contained therein or omitted therefrom, as to which such counsel need express no opinion)
comply as to form in all material respects with the applicable requirements of the Canadian Securities Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;The Purchase
Agreement has been duly authorized, executed and delivered (as a matter of corporate law) by the Company. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. None of the issuance of the Commitment Shares, the issue and sale of the Purchase Shares, nor
the consummation of any other of the transactions contemplated by the Purchase Agreement nor the fulfillment of the terms of the Purchase Agreement, will conflict with, result in a breach or violation of, or imposition of any lien, charge or
encumbrance upon any property or assets of the Company pursuant to (i)&nbsp;the constating documents of the Company, or (ii)&nbsp;any statute, law, rule, regulation, or, to the knowledge of such counsel, judgment, order or decree applicable to the
Company of any federal court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company or any of its properties or of any court, regulatory body, administrative agency,
governmental body, arbitrator or other authority in the Province of Alberta having jurisdiction over the Company or any of its properties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. To the knowledge of such counsel, no holders of securities of the Company have rights to the qualification of such securities under the
Canadian Base Prospectus or the Canadian Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. The Company is a &#147;reporting issuer&#148; under the securities legislation
of the Province of Alberta and is not on the list of defaulting issuers maintained thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. A court of competent jurisdiction in
the Province of Alberta (an &#147;<U>Alberta Court</U>&#148;) would give effect to the choice of the law of the State of New York (&#147;<U>New York law</U>&#148;) as the governing law of contract claims under the Purchase Agreement, provided that
such choice of law is <I>bona fide</I> (in the sense that it was not made with a view to avoiding the consequences of the laws of any other jurisdiction) and provided that such choice of law is not contrary to public policy, as that term as is
understood under the laws of the Province of Alberta and the laws of Canada applicable therein (&#147;<U>Public Policy</U>&#148;). Such counsel has no reason to believe that the choice of New York law to govern the Purchase Agreement (except as to
provisions in the Purchase Agreement providing for indemnity or contribution, as to which such counsel need express no opinion) is not <I>bona fide</I> or would be contrary to Public Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. In an action on a final and conclusive judgment <I>in personam</I> of any federal or state court in the State of New York (a &#147;<U>New
York Court</U>&#148;) that is not impeachable as void or voidable under New York law, an Alberta Court would give effect to the appointment by the Company of CT Corporation Services as its agent to receive service of process in the United States of
America under the Purchase Agreement and to the provisions in the Purchase Agreement whereby the Company submits to the non-exclusive jurisdiction of a New York Court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;If the Purchase Agreement is sought to be enforced in the Province of Alberta in accordance with the laws applicable thereto as
chosen by the parties, namely New York law, an Alberta Court would, subject to paragraph 11 above, recognize the choice of New York law and, upon appropriate evidence as to such law being adduced, apply such law with respect to those matters which
under the laws of the Province of Alberta are to be determined by the proper law of the Purchase Agreement (and in particular, but without limitation, not with respect to matters of procedure), provided that none of the provisions of the Purchase
Agreement, or of applicable New York law, is contrary to Public Policy and that those laws are not foreign revenue, expropriatory or penal laws; provided, however, that, in matters of procedure, the laws of the Province of Alberta will be applied,
and an Alberta Court will retain discretion to decline to hear such action if it is contrary to Public Policy for it to do so, or if it is not the proper forum to hear such an action, or if concurrent proceedings are being brought elsewhere and an
Alberta Court may not enforce an obligation enforceable under New York law where performance of the obligation would be illegal by the law of the place of performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;The laws of the Province of Alberta and the laws of Canada applicable therein permit an action to be brought in an Alberta Court on a
final and conclusive judgment <I>in personam</I> of a New York Court that is subsisting and unsatisfied respecting the enforcement of the Purchase Agreement that is not </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impeachable as void or voidable under New York law for a sum certain if: (i)&nbsp;the court rendering such judgment had jurisdiction, as determined under the laws of the Province of Alberta, over
the judgment debtor and the subject matter of the action; (ii)&nbsp;such judgment was not obtained by fraud or in a manner contrary to natural justice and the enforcement thereof would not be inconsistent with Public Policy or contrary to any order
made by the Attorney-General of Canada under the <I>Foreign Extraterritorial Measures Act </I>(Canada) or the Competition Tribunal under the <I>Competition Act</I> (Canada); (iii)&nbsp;the enforcement of such judgment does not constitute, directly
or indirectly, the enforcement of foreign revenue, expropriatory or penal laws; (iv)&nbsp;the action to enforce such judgment is commenced in compliance with the <I>Limitations Act </I>(Alberta); (v)&nbsp;in the case of a judgment obtained by
default, there has been no manifest error in the granting of such judgment; and (vi)&nbsp;no new admissible evidence, right or defense relevant to the action is discovered prior to the rendering of judgment by an Alberta Court. Under the <I>Currency
Act</I> (Canada), an Alberta Court may only give judgment in Canadian dollars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;No stamp or other issuance or transfer taxes or
duties or withholding taxes are payable by or on behalf of the Investor to the Government of Canada or the Government of Alberta or any political subdivision thereof or any authority or agency thereof or therein having power to tax in connection
with the issue, sale and delivery of the Common Shares by the Company pursuant to the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering such opinion, such
counsel may rely as to matters of fact, to the extent they deem proper, on certificates of responsible officers of the Company and public officials. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d684266dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;27, 2014 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oncolytics Biotech Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">210, 1167 Kensington Crescent NW </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Calgary, AB, Canada </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"><U>Engagement of Bayridge Securities, LLC </U> </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>as Placement Agent for Oncolytics Biotech
Inc.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter (this &#147;Engagement
Letter&#148;) will confirm our agreement with <U>Oncolytics Biotech</U> Inc. (the &#147;Company&#148;) with respect to the engagement of Bayridge Securities, LLC, a Delaware limited liability company, and a broker-dealer registered with the U.S.
Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority (FINRA) (&#147;Agent&#148;) as placement agent for the Company in connection with the placement of the Company&#146;s common shares to Lincoln Park
Capital Fund, LLC (the &#147;Investor&#148;), as more fully described herein. Agent hereby agrees, on a best efforts basis and subject to the satisfactory completion of its continuing due diligence, to place up to Twenty-six Million Dollars
($26,000,000) of the Company&#146;s authorized but unissued common shares (the &#147;Common Shares&#148;) with the Investor, as more particularly set forth below and subject to the terms and conditions of this Engagement Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Shares will be offered and sold on such terms as the Company and the Investor may agree upon pursuant to a Purchase Agreement to be entered into
between the Company and the Investor (the &#147;Purchase Agreement&#148;), and the offering and sale of such Common Shares shall be registered under the Securities Act of 1933, as amended, pursuant to an effective registration statement on Form F-10
(File No.333-182260) filed with the Securities and Exchange Commission (the &#147;Registration Statement&#148;). Agent will use no offering materials other than the Company&#146;s publicly filed reports and the Registration Statement, including the
prospectus contained therein or any prospectus supplement thereto, or any amendment or supplement to the Registration Statement or the prospectus contained therein, as the Company will have approved in writing prior to their use. The parties hereto
agree that the Common Shares will be offered and sold by the Company in compliance with all applicable federal and state securities laws and regulations. The placement of the Common Shares by Agent to the Investor as contemplated hereby may be
referred to herein as the &#147;Offering&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of Agent&#146;s engagement (the &#147;Engagement Period&#148;) as placement agent for the offer
and sale of the Common Shares to the Investor will commence on the date of actual receipt by Agent of an executed copy of this Engagement Letter from the Company and, unless extended pursuant to the further written agreement of the parties, will
expire upon the earlier of (i)&nbsp;the termination date as set forth in the Purchase Agreement, (ii)&nbsp;the date </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that all the Common Shares under the applicable prospectus supplements forming a part of the Registration Statement have been issued and sold to the Investor, (iii)&nbsp;the date that the
Investor has purchased the maximum number of Common Shares permitted to be purchased under the Purchase Agreement, (iv)&nbsp;the date that the Offering or the Purchase Agreement is terminated by the Company or the Investor or (v)&nbsp;if the Company
so elects, the date that Agent breaches any representation or covenant in this Engagement Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company hereby represents, warrants and covenants
that: (i)&nbsp;it shall provide to Agent in a timely manner information that is responsive to the transaction questionnaire provided by Agent to Company in connection with this Offering; (ii)&nbsp;it shall complete and provide to Agent a description
of this Offering and other related information to be included on the Filer NotePad in connection with the FINRA Rule 5110 filing to be made in connection with this Offering; and (iii)&nbsp;its current shelf registration and initial base shelf
registration is complete and accurate and ready for use in this Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly following the date that FINRA issues a &#147;no objection&#148; letter
in connection with the Offering pursuant to FINRA Rule 5110, and provided that the Initial Purchase (as defined in the Purchase Agreement) has been consummated, the Company hereby agrees to (i)&nbsp;pay Agent a placement fee equal to Ten Thousand
Dollars ($10,000) in connection with this Offering, which placement fee shall be payable to Agent via wire transfer in accordance with the wiring instructions annexed hereto as Attachment B and (ii)&nbsp;within ten (10)&nbsp;days of Agent&#146;s
request, the Company shall either (A)&nbsp;reimburse Agent for its reasonable, documented, out-of-pocket legal expenses incurred in connection with the preparation of any filings required to be made on behalf of Agent in connection with the Offering
pursuant to Rule 5110(b)(7)(C)(i) of the Financial Industry Regulatory Authority (&#147;FINRA&#148;), or (B)&nbsp;pay such legal invoice directly to Agent&#146;s counsel, provided that Agent has not previously paid such invoice itself, in each case
up to a maximum of Five Thousand Dollars ($5,000) in the aggregate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties hereto acknowledge and agree that the engagement of Agent hereunder is
not intended to confer rights upon any person (including shareholders, employees or creditors of Agent) not a party hereto as against the Company or its affiliates, or their respective directors, officers, employees or agents, successors or assigns.
Agent shall act as an independent contractor under this Engagement Letter, and this Engagement Letter does not create any partnership, joint venture or other similar relationship between the Company and Agent and any duties arising out of
Agent&#146;s engagement shall be owed solely to Company. Agent shall have no authority to bind or obligate the Company in any way without the Company&#146;s prior written consent. At all times during the term of this Engagement Letter, Agent shall
comply with all applicable laws, rules and regulations with respect to the services provided by Agent hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Engagement Letter is for the
confidential use of the Company and Agent only, and may not be disclosed by the Company or by Agent (in whole or in part) for any reason to any person other than their respective Board of Directors, executive management or other employees with a
need to know, or its attorneys, accountants, investment banks, financial advisors, the Investor or other persons or entities that have a reasonable business reason to review this Engagement Letter, and then only on a confidential basis in connection
with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the proposed Offering, except where disclosure is required by applicable law, stock exchange or Nasdaq rule or regulation, or is previously agreed to in writing by the Company and Agent. The
parties hereto acknowledge and agree that, notwithstanding the preceding sentence, (i)&nbsp;the arrangement contemplated hereby will be disclosed by the Company in the Registration Statement and this Engagement Letter may be filed with the SEC in
its entirety by the Company in its sole discretion, and (ii)&nbsp;the arrangement contemplated hereby may also be disclosed by the Company in its reports filed pursuant to the Securities Exchange Act of 1934, as amended. The terms of this Engagement
Letter will be governed by and interpreted in accordance with the laws of the State of California, and any disputes arising hereunder shall be exclusively and finally settled by an arbitration administered by the American Arbitration Association in
accordance with its Commercial Arbitration Rules in San Francisco, California. The arbitration shall be conducted by a single arbitrator mutually agreed upon by the parties. The determination, finding, judgment, and/or award made by the arbitrator
shall be made in writing, shall state the basis for such determination, shall be signed by the arbitrator and shall be final and binding on all parties, and there shall be no appeal or reexamination thereof, except for fraud, perjury, evident
partiality, or misconduct by an arbitrator prejudicing the rights of any party and to correct manifest clerical errors. The arbitrator shall award to the prevailing party, if any, as determined by the arbitrator, its reasonable attorneys&#146; fees
and costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company hereby agrees and represents that: (i)&nbsp;it will comply with all applicable federal and state securities laws and regulations
with respect to the Offering and (ii)&nbsp;Agent may, at its option and expense (and only after the first public disclosure or announcement of the Offering by the Company) place announcements and advertisements or otherwise publicize Agent&#146;s
role in facilitating the Offering (which may include the reproduction of the Company&#146;s logo), stating that Agent acted as placement agent in connection with such transaction; provided, however, that Agent shall first submit a copy of any such
announcement or advertisement to the Company for its approval, which approval shall not be unreasonably withheld. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agent hereby agrees and represents
that: (i)&nbsp;Agent is a broker/dealer registered with the U.S. Securities and Exchange Commission and a member of FINRA in accordance with all applicable laws and regulations in each jurisdiction in which Agent intends to use its best efforts to
place the Offering, and payment of the placement fee contemplated under this Engagement Letter will not jeopardize the Company&#146;s compliance with applicable federal and state securities laws or regulations; (ii)&nbsp;Agent will not make any
representations to the Investor about the Company other than information included in the Company&#146;s public filings or otherwise conveyed to Agent by the Company in writing; (iii)&nbsp;Agent will not do any advertising or make any general
solicitation on behalf of the Company in connection with the Offering; (iv)&nbsp;Agent will comply with all applicable federal and state securities laws and regulations with respect to the Offering; (v)&nbsp;Agent is not affiliated with the Investor
or the Company; and (vi)&nbsp;Agent agrees to keep confidential any nonpublic material information about the Company conveyed to Agent by the Company or on its behalf. In further consideration of Agent&#146;s placement of the Common Shares, the
Company and Agent agree to be fully bound by all of the indemnification provisions set forth on Attachment A, a copy of which is attached hereto and is fully incorporated herein by this reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties acknowledge and agree that nothing contained herein shall modify or affect the rights or obligations
of the Company and the Investor under the Purchase Agreement. This Engagement Letter and all rights and obligations hereunder may not be assigned by either party without the prior written consent of the other party. This Engagement Letter may be
executed in counterparts and/or via facsimile transmission or the exchange of PDF copies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the foregoing is acceptable, please sign and return to us a
copy of this Engagement Letter, which will represent the entire agreement between the Company and Agent with respect to the matters addressed herein and will supersede all previous oral or written agreements or understandings of any nature
whatsoever between the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to working with you. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Sincerely,</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD COLSPAN="5" VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Bayridge Securities, LLC</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><U>Oncolytics Biotech</U> Inc.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ &#147;Anton LeRoy&#148;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ &#147;Kirk Look&#148;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Anton LeRoy</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Kirk Look</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">COO</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attachment A to Engagement Letter </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Company Indemnification Provisions </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Oncolytics Biotech</U> Inc. (the &#147;Company&#148;) agrees to indemnify and hold harmless Bayridge Securities, LLC (&#147;Agent&#148;), and any of its
directors, members, officers, employees, consultants or agents (collectively, the &#147;Indemnitees&#148; and each individually an &#147;Indemnitee&#148;), to the fullest extent permitted by applicable law, from and against any and all claims,
losses, damages and liabilities, including without limitation, reasonable legal, accounting and other professional fees and related costs and disbursements and other reasonable costs, expenses, or disbursements relating thereto (collectively, the
&#147;Liabilities&#148;), directly or indirectly, based upon or arising out of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">any untrue statement or alleged untrue statement of a material fact contained, or incorporated by reference, in the Registration Statement of the Company (the &#147;Registration Statement&#148;) relating to the Common
Shares being placed by Agent with the Investor (as defined in the Engagement Letter between Agent and the Company to which this Attachment A is an integral part (the &#147;Engagement Letter&#148;)) in connection with the Purchase Agreement to be
entered into between the Company and Lincoln Park Capital Fund, LLC (the &#147;Purchase Agreement&#148;), including any preliminary prospectus or prospectus contained therein or any prospectus supplement thereto, or any amendment or supplement to
the Registration Statement; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">the omission or alleged omission to state in the Registration Statement or any document incorporated by reference in the Registration Statement, a material fact required to be stated therein or necessary, in light of
the circumstances under which they were made, to make the statements therein not misleading. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary
contained herein, (a)&nbsp;the foregoing indemnity shall not apply and the Company shall not be liable to the extent that a court of competent jurisdiction shall have determined by a final judgment (with no appeals available) that such Liability
resulted directly from any acts or failures to act, undertaken or omitted to be taken by any Indemnitee constituting breach of contract, gross negligence, bad faith or willful misconduct, (b)&nbsp;the foregoing indemnity shall not apply to any
Liability to the extent arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by Agent expressly for
use in the Registration Statement, any preliminary prospectus or the prospectus contained therein or any prospectus supplement thereto (or any amendment or supplement thereto), and (c)&nbsp;with respect to the Prospectus (as defined in the Purchase
Agreement), the foregoing indemnity shall not inure to the benefit of any Indemnitee or any such person from whom the person asserting any Liability purchased Common Shares, if copies of the Prospectus were timely delivered to Agent and a copy of
the Prospectus (as then amended or supplemented, including, without limitation, by any Free Writing Prospectus (as defined in the Purchase Agreement), if the Company shall have furnished any amendments or supplements thereto) was not sent or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
given by or on behalf of Agent or any such person to such person, if required by law so to have been delivered, at or prior to the written confirmation of the sale of the Common Shares to such
person, and if the Prospectus (as so amended or supplemented) or delivery thereof would have cured the defect giving rise to such Liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect
to a particular Indemnitee, if and to the extent the relevant Liabilities are determined in a final judgment by court of competent jurisdiction (not subject to further appeal) to have not been indemnifiable hereunder, such Indemnitee shall promptly
repay all amounts already paid by the Company to such Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to provide for just and equitable contribution, if a claim for indemnification
pursuant to these indemnification provisions is made but it is found in final judgment by a court of competent jurisdiction (not subject to further appeal) that such indemnification (i)&nbsp;is due pursuant to the terms hereof but may not be
enforced in such case for a reason other than due to the Indemnitee&#146;s breach of contract, bad faith, gross negligence or willful misconduct, or (ii)&nbsp;would be due pursuant to the terms hereof but for the fact that such indemnification may
not be enforced in such case for a reason other than due to the Indemnitee&#146;s breach of contract, bad faith, gross negligence or willful misconduct, then in each such case the Company, on the one hand, and the claiming Indemnitees on the other
hand, will contribute to the losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses and disbursements (collectively, the &#147;Losses&#148;) to which such Indemnitees may be subject. Said contribution will
be made in accordance with all relative benefits received by, and the fault of, the Company on the one hand, and such Indemnitees on the other hand, in connection with the statements, acts or omissions which resulted in such Losses, together with
the relevant equitable considerations and will be determined pursuant to the arbitration provisions set forth in the Engagement Letter. No person found liable for fraudulent misrepresentation will be entitled to contribution from any person who is
not also found liable for such fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligation for indemnification contained herein shall not apply unless
the Indemnitee furnishes to the Company, on request, information available to the Indemnitee for such defense and the Indemnitee cooperates in any defense and/or settlement thereof as long as the Company pays all of the Indemnitee&#146;s reasonable
out of pocket expenses and attorneys&#146; fees. The Indemnitee shall not admit any such claim without prior consent of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Indemnitee will
give prompt written notice to the Company of any claim for which the Indemnitee seeks indemnification hereunder, but the omission to so notify the Company will not relieve the Company from any liability which it may otherwise have hereunder except
to the extent that the Company is damaged or prejudiced by such omission. The Company shall have the right to assume the defense of any claim, lawsuit or action for which the Indemnitee seeks indemnification hereunder, subject to the provisions
stated herein. After notice from the Company to the Indemnitee of its election so to assume the defense thereof, and so long as the Company performs its obligations pursuant to such election, the Company will not be liable to the Indemnitee for any
legal or other expenses subsequently incurred by the Indemnitee in connection with the defense thereof; provided, that, if any action, suit, proceeding, or investigation commenced which gives rise to a claim
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for indemnification and which, in any Indemnitee&#146;s reasonable judgment, gives rise to a conflict of interest between the Company and the Indemnitees, then the Indemnitees will have the right
to retain legal counsel of their own choice to represent and advise them, and the Company will pay the reasonable fees, expenses and disbursements of one (1)&nbsp;law firm for all Indemnitees incurred from time to time in the manner set forth above.
Such law firm will, to the extent consistent with their professional responsibilities, cooperate with the Company and any counsel designated by the Company. The Company will not be liable for any settlement of any claim, action, suit or proceeding
effected without its prior written consent; provided, however, that the Company will be liable for any payment of any award or settlement of any actual, potential or threatened claim against any Indemnitee made with the Company&#146;s prior written
consent. Neither the Company nor any affiliate thereof will, without the prior written consent (not to be unreasonably withheld or delayed) of the Indemnitee seeking indemnification, settle or compromise any actual, potential or threatened claim for
which indemnification is sought hereunder, or permit a default or consent to the entry of any judgment in respect thereof, unless such settlement, compromise or consent includes, as an unconditional term thereof, the giving by the claimant to the
Indemnitees of an unconditional release from all liability in respect of such claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any provision contained herein to the contrary, the
obligations contained herein for indemnification and contribution shall not apply to any action, suit or proceeding brought by a party hereto against the other party hereto. Further, the Company&#146;s obligation for indemnification and contribution
contained herein shall not apply to any action, suit or proceeding brought against Agent by any governmental, regulatory, or self-regulatory agency or body based upon an alleged violation of laws, rules or regulations governing financial advisors
and/or broker-dealers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither termination nor completion of the engagement of Agent pursuant to the Engagement Letter will affect these indemnification
provisions, which will survive any such termination or completion and remain operative and in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attachment B to Engagement Letter </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wiring Instructions </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First Republic Bank </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">111 Pine Street San Francisco, CA 94111 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bank ABA/Routing #:
321-081-669 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Account #: &#145;800-0049-8692 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Account name:
Bayridge Securities, LLC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 8 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>d684266dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g684266tx_pg65.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">210, 1167 Kensington Cr. N.W.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Calgary,
Alberta</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Canada T2N 1X7</P></TD></TR>
</TABLE> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR IMMEDIATE
RELEASE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Oncolytics Biotech&reg; Inc. Announces Initial US$1.0 Million Investment and Up to US$25.0 Million </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CALGARY, AB, February&nbsp;27, 2014 &#151;</B> Oncolytics Biotech Inc. (&#147;Oncolytics&#148; or the &#147;Company&#148;) (TSX:ONC; NASDAQ:ONCY) announced
today that it has entered into a share purchase agreement (the &#147;Purchase Agreement&#148;) with Lincoln Park Capital Fund, LLC (&#147;LPC&#148;) that will provide an initial investment in Oncolytics of US$1.0 million and make available
additional periodic investments of up to US$25.0 million over a 30-month term (the &#147;Financing&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon execution of the Purchase Agreement
today, Oncolytics received an investment of US$1.0 million in exchange for the issuance of 600,962 common shares to LPC at a per share purchase price of US$1.664. In addition, subject to the terms and conditions of the Purchase Agreement,
Oncolytics, at its sole discretion, may sell up to US$25.0 million worth of common shares to LPC over the 30-month term. The purchase price of the common shares will be based on prevailing market prices of Oncolytics&#146; common shares immediately
preceding the notice of a sale without any fixed discount. Subject to the Purchase Agreement, Oncolytics controls the timing and amount of any future investment and LPC is obligated to make such purchases, if and when the Company elects. The
Purchase Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on the Company&#146;s future financing activities. Oncolytics can terminate the Purchase Agreement at any time at its sole discretion without
any monetary cost or penalty. The Company will issue a commitment fee in common shares to LPC in connection with the Purchase Agreement and on a pro rata basis as the US$26,000,000 is funded by LPC. LPC has also agreed not to cause, or engage in any
manner whatsoever in, any direct or indirect short selling or hedging of the Company&#146;s common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are very pleased to have entered into
a share purchase agreement with Lincoln Park Capital,&#148; said Dr.&nbsp;Brad Thompson, President and Chief Executive Officer of Oncolytics. &#147;The initial investment and commitment by LPC provides us with increased flexibility as we continue
with our clinical programs.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has filed a prospectus supplement, dated February&nbsp;27, 2014, with respect to its U.S. registration
statement on Form F-10 (the &#147;Registration Statement&#148;) and Canadian final base shelf prospectus (the &#147;Base Shelf Prospectus&#148;), each dated July&nbsp;3, 2012, pursuant to which the Company may issue up to US$13,300,000 of common
shares pursuant to the terms of the Purchase Agreement (representing an aggregate market value of not more than 10% of the market value of the Company&#146;s outstanding common shares based on the determination date under applicable securities
laws). Pursuant to the Purchase Agreement, the Company may file additional prospectus supplements in the United States and in Canada in the future to qualify the sale of additional common shares to LPC that would result in aggregate gross proceeds
to the Company of up to US$26,000,000. No offers or sales of any common shares will be made in Canada pursuant to the Purchase Agreement or the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company plans to use the net proceeds for working capital and other general corporate purposes, including funding ongoing operations </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The common shares to be issued in the Financing have been approved for listing on the NASDAQ. The Toronto Stock Exchange has accepted notice of the Financing
and the Company is relying on the section 602(g) exemption under the Toronto Stock Exchange Company Manual. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be
any sale of these common shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Oncolytics Biotech Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oncolytics Biotech Inc. is
a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using
REOLYSIN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <U>www.oncolyticsbiotech.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Lincoln Park Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Park Capital (LPC) is
an institutional investor headquartered in Chicago, Illinois. LPC&#146;s experienced professionals manage a portfolio of investments in public and private entities. These investments are in a wide range of companies and industries emphasizing life
sciences, specialty financing, energy and technology. LPC&#146;s investments range from multiyear financial commitments to fund growth to special situation financings to long-term strategic capital offering companies certainty, flexibility and
consistency. For more information, please visit: <U>www.lpcfunds.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements within the meaning of
the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in
this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in the future, including such things as the proposed offering of common shares and the intended use of proceeds and other
such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties, which could cause the Company&#146;s actual results to differ materially from those in the forward-looking statements
and forward-looking information. Such risks and uncertainties include, among others, risks related to the market conditions of the offering and risks related to the Company&#146;s business which may result in the intended use of proceeds changing.
Investors should consult the Company&#146;s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statement and forward-looking
information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as
required by applicable laws. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Equicom Group</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Dian Griesel, Inc.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Nick Hurst</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Susan Forman</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">300 5<SUP STYLE="font-size:85%; vertical-align:top">th </SUP>Ave. SW, 10<SUP STYLE="font-size:85%; vertical-align:top">th </SUP>Floor</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">335 West 38<SUP STYLE="font-size:85%; vertical-align:top">th </SUP>Street, 3<SUP STYLE="font-size:85%; vertical-align:top">rd </SUP>Floor</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Calgary, Alberta T2P 3C4</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">New York, NY 10018</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tel: 403.218.2835</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Tel:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">212.825.3210</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax: 403.218.2830</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">212.825.3229</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>nhurst@tmxequicom.com</U></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><U>sforman@dgicomm.com</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g684266tx_pg65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g684266tx_pg65.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`00$R`P$1``(1`0,1`?_$`+L``0`"`@(#`0``````
M```````("0<*`08"!`4#`0$``04!`0``````````````!`$"`P4&!P@0```&
M`0,#`@,$!0@%#0````$"`P0%!@<`$0@A$@DQ$R(4%4%181:AT3(C%_"!D;%"
M)!D*<3.S)3;!X5)RLD-S=+0UEF<Y$0`!`P(%`00'!@0$!P`````!``(#$00A
M,1(%!D%187$3@9'!(C(4!_"AL5(C,]%"-!7A@B06\6*R4V,U%__:``P#`0`"
M$0,1`#\`W^-,L47YF4*7?XB[[".PCMZ=1'\`#5A=I'F.($7:>Q5HJB^7/F7X
MO<99*2I-75>9VRFP7.Q<U>@/&HU^&D@[B`RL%S4(XCD7A%0V.V9)OG!1W*8I
M#!MKS[>_J-M6U2NMK=KI[H8`-Q%?0ID-E)*-1P:H*0?/?S/\B5TYK`_$&N4F
MG.C"I&OK+4)0C5PU4`!14/8<@V>IMGVQ#`(F;-"E$1W`-M:.+E?.]W87[591
MQXU&MKB*=^(Q[%E\FP8:2/<3W9+W).X_YB:&54G5*;0I=J0?<-7HN*PF^(!`
M^(4D6R$VUE%2@4-NCHR@_8(CJ-+>_59CA*^*-P_*QOL5Q;MSA1A(/>O4@?-1
MRGX^3[*L<[.($_6F:JI&ZEJK43,TQ^8>XI3N6<99%)&L6`I0W'L:R2'=OT'5
M6?4?>]I->1V#Q;U`+V@BG;7"B&RBD:3"[$*\OC5R[P'RTJ9[=A&^QEF1:%2"
M;KZ_=&6^L+J`40;6*MO.R0CS=QMBJ@4[940_=J'UZ;M&_;?O$#;BUEC<QPJ`
M#B.X@]5!EMYH3[X]WM4E@$!#<.H:W0(=B,EA7.JHFB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O$Y@*'7[>@
M?B(]`#^<=8Y'M90.-`46M-SVYO9NY;9T/X_.!KAVN==\\@,KY+@'ZC+Z@9H8
M$;'%M+&UW_+U"K1!,65D4S`J]6#Y=$1+T5\?Y-R*_P"0;D[B?'31[#1[^A'6
MAKA3_%;:TAB@:VZN*T!J.S#M'7P5AO!_Q1\=^(D5%V&6@X[+&;1125E\DVN-
M0>MHI^8H*+H4.#>`NTKS%%<1`CD2GD5MNXZH=W87K..<)VS986R3M,VX.^)S
MSJH>[#!1[R]DN'G11L9Z#!6E%3`GH)N@``;F$0``#8``/3;7;@```8-'09*"
M,J+SV_'^K]6A%>Y%U2YT2F9$K\A4[[5H&Y5B604;2,!9HIE-1+M)0AB""C)^
MBNB!P*8>TX`!RCU`0'KJ/=6UO=P.@NFMDA<,6N`(*N:YS35I(*UN.97C(R-P
MTLZG,OQSS=CK*U+%S.7#$\>X=2KB)@4OW\HXK*"YUEK13`2*89&"=@X.1#=1
M`P@3M)X[O_#[S87_`-^XO5F@U?'FTXU)#<.F"VMO=,E:8KK%IR5L_CLY[4_G
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M*+_&;.D;'V^U2+U(#2<)57Y`?U2GIKJ![Z8),ER/'O4!6>+CW;^V3:#P'CHV
MS;VWUPVNXR?$\YD?A]RS75QYC1!7])N0^V*N`V`->AAH!KU4/+!<ZJB:(FJ%
MH=FB_%9(JI#E$H&[B"78P`8H@("`E,4?A,40'80'H(:L+&N)8[]LMH55:J7(
MVL+^*+R9XVY!T!$\-QWY#/7:%PKS(HI1$>REI1FVR/7$D0[&Y$H-\^;V",3#
M8J.YDR@!2B&O$MR@?P;E#;^W_H;DM!ID2<QUI^*VK)C=6YCE-7`8>C);5#%T
MW>M&SMJN1RV<H(N6SE,Q3)N&[A,JR"Z9B_"9-5(X&*(>H#KVV&1DT398Q2-P
M!'@5J`'`4=B5[>LBJFB+@3``@'7KHBYT1-$7@)R^F^XAZ@&B+R`P&]-^FB+G
M1%P([!OHBX`Q1'8!Z_=]NB+RT1-$31$T1-$31$T1-$31$T1-$31$T1-$7&_4
M0^T-$7.B)HB:(FB)HBUE_,H57,W/#@3QC=*J*P$M(PTG)L@.;VU#7S(C."?G
M,F`[&-]"JJI`$?0IS!]NO&_J'6]Y-M6V&IA<2YS3\)H:XCK1;"!H^6<^GO5S
M6R\U:H-&Z+9LDFBW;IIH-T4B@1)!!`A4D44B%`"D332(```=``->NQ4;"UK,
M&X>I:\@$XYKVM9T31$T1-$35"`<#DBI8\\.-8^Y\&).W*MDCR>*\A4NS,'/:
M`K(,IQ\:H3""9MNXJ;E&;2,8`]12#U$`UYW]3+1DG'//`&N*4$'J.TCL4[;3
M_J"TY$*;GCTO[[)_";C-<Y-<SF2D,3UN.D'!S=RBSVM)*5ERJJ;U%116'$3"
M/41'70<5NG7>QVLSB2718U[B1[`L-TT-N'`8"JP+Y*O(3-\"(O$;^%Q>QR<X
MRC-6>*%J]LCJO_3/R\TBW"0MP:Q4H=\J]4DP)V=I1+V]-Q'6IYKRRXXM%`88
MA(^62F/8K[:W-R=+<PLA\$/(#C/G!1WS^%;FI65:D?Y;(N)91\"\U7506,@2
M6C55D6:TS6G:I>TKD$2'06`R*Q2'`.Z=QGE-GR)FESA'N0SC!.2QW%NZ,T6,
M_(UY$YC@M/8)AXO%T=D0N8I.;CW+A[9G<`>"+#O:XU!5NFVBI$KTS@)T1^(R
M?:*8!U[NF#E7*7\??#$&!S9W!M?RU-*I%`96.D'PM%?:K1&RIE&Z*QO51))0
M0`=]O<(4VV^P>@FUUT;R]C9&Y.8#ZU@<0!50KYA<^\"\+8F)#),E+SU[M/<6
MEXLI30DU>;,/O`U(X28>ZFC&1AWIRHE<N3IE46'L2!0X"76BWWDNW[`T-GU2
M7#B*,;GCU\`LL=K/*-<8)`4=(/D[Y-\F,$[/C_@10:)6'J17<2QSAG1*#N;M
MDH`*('>04+"JJQ;A8@_L.`3$HCL.M)%OG)KS]6SL2V"E07FE1ZPLGEP`4>[W
M^Q2-XVYFY>7RT3]9Y&<3X_![&%8D7:WJ#RW7[M79]ZJH!4HV(BVC4)=4PD`R
MBBQQ(FB4``P"(@&MUM6X;[=3EE_;")@IVXK&]L8IY9JI29%R'3<44NR9$R#8
MH^JTNHQ3B:L4_*+^RRCH]L&YU3B`&5554.)2))$*9154Q2$`QC``[2_O8;"!
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MN[(F8S9V@HJV<E*/8?N*8I>CV'D%ER*S%S9AS)`!J8[XFGJUW>,BHD\#[7XB
M2U>US2Y%/.*/&S(^>V%70NCJAM(9PE6G,HK#(21I:P1<)VJ22+5ZHV!`LD*F
MX)&[NS;IOOJSD.\R[)M9OXF!].U9(6![M)ZKT>$7)5[RXXWT3/,A5&](=W)Q
M8D5*TTEE9INQ^@V&1@RF)(+-&*BWS)6/N"`IE[1-MUVWUDXWN[]^VB/<GM#"
M_H%2>$V[]#LU+?6\.6."Q*JGGOSOSGP=GJY;7''1AD_CK+O(QC,9'@+?(L[!
M5)%=4I'T5.P9X9Q'LEG1!$T:Y.N#5R8/:.=-0``>)Y)R/=>.N8\6[9;)S@"\
MY@',^A2HHA(T]JG?@W/&,>1&,JYES%-G:V6EV-H"R#Q(X)NXUZF4OS\)/,CC
M[L3-1*INQR@IL*8AN`B02F'H[#=]OW*S%[:2:H>O<>Q1WQ.#Z8JMBX^4V7N?
M*IIQ5X:8<:<C)N-45;W[(;BW+UW'M26;.R(2SGZNPAY@CV$KQ-RN7FY4W#K^
M[M06/Z\I)S*6\WMNT[/&)6@_J'\O9Z\?4I)@TQZW9E62YBL^8:GC"3G<08ZA
MLKY1:)1`QM%?6Y&F0\LLN\;(3(DLLFW53:(L&QU5DO=3`RH$`O01UU>Y3W<%
ML'6C==R/Y>]8&-C)]\T55V?O(;SRXQ8Y?Y8S+P4HM;HL;)Q$.\E67(B)GUTG
MTXY^3CB?3HF"</#IJN1`@F`NQ!$!'IKA]UY9R;9[<7EW9,$%:=?XJ1'!!*_0
M'&J[-B?F[Y%,V8YJ&5\<\!Z#,4>]1"<[691UR2@HI=[&+*JI)+JQS^%3>M#'
M.B;8BA0-MU^W6?;>3<EW2V9?6UFPVL@JTXXT)!Z]H*K+;P0R&,N-0K3\5S>0
M+!C^JS64Z>PH&09*(1=6NF1-@2M,=6Y90ZGN1;6P(H-D)8J"0%[E2$`@F$0#
M<`W'M[*6>6U\RX&FXS</RGJ!X*(Z@.&2KCR]Y'YW&'D,Q=PA0Q;&S$1D(:61
M?(*MG=M)&+-;6DNZ,*4$2+5;.BL1C0*'<N43@<=]MM<C?<N?:<H9L&@5<UIK
MXT4H6U;;S1FK7Q-\`F#?T$?QZ;_IUWA-!50R*B@57/(7RC8SQ?E<G'3"N/[O
MRDY%'<*,W..<7_+DCJ^\22]QPVL]K<E79,'$>00,Z3127^4+_KS)&Z:XJ^YE
M:0W1L-I'S-_JHYOY3]NBDQ0>YJ>?=`7S`SOY8%FHSC?@W@INQ,4JR=9?<CTO
MS?[(['%!19**&!(\[?A[15V[^FL+]XYBUFIEC&XG(8X#KUJGEV_YBIM<<LBY
MER90_P`PYPP<O@*W!(.F9:8YNT-=UG#-N($"8^=A$$4&*#I4#`DBH)E13`#B
M(`8`UU&UW%]/;!^X1^7.3DL3VQC]LU46^=WDDQQPH>4ZCJ5"QY2S+D5%-S3,
M<UMPWC@69N)(L*QD)N;<D7(P;R$P;Y=NDDBX<.%"'V(4I>[6@Y-R^#CSV0%N
MJYDJ`#W4_BC(R^M,PN@LLV>7*:CTIQGPYXUU]LY1!RA5K+GF4-;$4E`!1%N^
M6CX\T.V>"D(`8HG#M/OOMJ,S<>931MN6VC!&X5`ZT[P357AD5/U#0K.7&CD#
MRWR)>9.C<AN&TG@YO$1*L@?(T;DRM7"C2;KW"(MXJ,0:E)*NG;HW<8!3,H5)
M,!%3MW+OLMJW7?+B[-ON%J(XZ#W@K'AC31AJU3P_I]?OUTND?F/K5BUG/)PN
M6C^7/Q^9%EMDH!R&-F`N5![$4U8G+$TU>B<X_"7V0L:!A$>@%'7C'-2;3G%A
M>.^'`=V)`6VMJ&R<.N/X+9C#7LT8I4=ZU)7.LJHFB)HB:(FB*I?S:V5E7O'G
MEIHZ4(5Q:Y['58CB&$-U'KFYQ4H)$P]3'(RB%C_@!1'7!_4B9L7%Y6&E7N`"
MF6(/G@A9D\5T`ZK?C[XNQSU-1-RMCKZR9-4#`<J-AGIJ=:[@;<?B:R"8ZF\(
M@^7XQ;18X1_B7*E[_5/\?8%5/_F*5CMX?B&NF82';W7(:Y3!Z@=%C4U"B'7U
M`Q=</]5:Z]OK^<*1MQ_3DIG59"YM<"LHTRP5;R"<#G3RKYQ@H&)L^2<?5U$I
M6]]:FB&SB:G(B()V-I61DFP"26B#E$DLENHF`.@W/,WSC5U;!G)^/D-N&Q-)
M;E@&@U[Z]1[%2"Y:X_*W7K59WD(YM4WG+C'A;>(]HG5LG47(UBJ^6\>**&%>
MOS\@I2UVLI%%7[73JKS:D8X,V.8/<;J)G06V4)N;BN4\@BY%;;;(?_:MGC,H
M&0&H5PZ*59L+9)/R:2MSMGO\BTV]?E6NWV_]RGZ^FOH:`$V\>C_MM]BTQQ>[
MQ6IQG]<N.//%2[ER2638XY?V^H2E$G['TK#>MC1SP],=).G0?(MXZ`O6Y7)M
MP*V=[J*;`/=KQ/=C\I]2&7.YU^0U@#5\..6>%%M+8D6,@!H_QQ6V8T517117
M1537170362624*LBLDH4IR*I+$$Q%4U"F`2F`1`P#N`Z]QC<U[G20D&$TI3+
MT4P]2U(!TXC&J_<3EZ;AMUV#NZ;C^'0=]9*@&A(J514]><ZMW>Q\"[.-.;/G
MC*O7ZBV:]-H\BBJHTF-=ODWSIPBF`BJPC99RR<+[AVD(GWCT+OKSOZGV\\_&
MG"+5H$@+M-:T]'13MOI\P*KO/AIN%,LWC]PE&U)Q''>U!.S5JYLFBB0NV%M1
ML\Q(/5))(FZA%Y-J^1=)G/L*B*I1`1#TS?3ZXMY>/0M@+0&N<",C44K4=_>K
M+RIG)5FT\\B(Z'EI">68M(-C'/7<TZDE$DHYO$MVJBLBN^47V0(T29E.*HG^
M'LWWUVEX^WC@?\R0V'RG=:=M5&:#J:&U6J9X'6<@^YD\J+#2DW(8G+49YK[[
M=-4D*<TCDE-Y0V13=OL_-EA472J)?VRH"80V*.O$OID+G_<M^Z&OR9+M)QH1
M4TQRJMO?EIB&55<GYB0[O'3R'_L_[NIO\V]^JX?HWUZ#STTXG==M/:H%E3YI
MO95?&\+H"7QVX/Z"/<]R".^WH'Y_L0?UAK%]/*_[5MQ_S?P5]_\`U3NQ6H]P
M;@7KN/I]WH(_U!KO%"76+G3:MD"K3]+NL#%V>J6B-<PT_`3+1-[&RL8\3%)R
MS=MU0$IR*%'<!#8Y#`!BB!@`0CW4#+J!UO*`Z-XTFN.!S5S7ECJA:;O+W$67
M?'MR*G.)?&K,\_7</\RHVL)(Q#IPX,[KD;:+B:J#&.Y!/^\I.H]Q[C;Z@T%)
MVZB5!15$3;CKYYWO;;[C.Z'8-ID(VJ\.DU.()Q-,?P6UC(N8\1[S<5L^\)^$
MF)N$>+&]"Q^T))V243:/,@Y"?M4BV"ZSJ28D,LX.7N^1A&1A,1BP3$4FR?7X
MU#'4/[1Q?CUIQZQ%M#[UT0"]QQ)/CG08T6MEE,AI_*%,[8/NUTRQ*GGSH;?X
M?5X].F0<7B/_`,G2UY_]3#3BTA.`\QOM4[;:?-8Y:5)+Q??_`)_<4Q_^IXC_
M`-8_UL^$5'&;7L\L_P#4Y8[S^I=]NBGF'IKJV#W0HJU<N6.W^/MQJZ^JV&1V
M^[:+M(;Z\1WPC_Z=9>`KZ@MO#_0.[,?:MF^RI2[BL6!"OK$;SR\'+(PCA00`
MB$NJQ<)QBQQ'H!$WIB&'\`U[3="1UK(V']XQNT^-#3[UJ1F/%:J_@DD8.A<K
M^3E#S(9&O\@I.,2B8]M;#?+6)[*15IE760XIDL_$J[B4>/E6CI5,@BHX13]P
MNY"B.O$OIRZ&UY)?0[E1NX/<=.J@J:XTKF:=BVE[^PVBVPNXI?A$!$?M^$>O
M7]/77NN-*]%JJ+SW#IZ!OU`/M^[J&WXZL<X`5S0*$G+_`(#<?N:D9%%RG#R<
M;<ZR@NA3\E5!\$1=*V11?YL&J+P4EVTC%%??OOEG*2A`4^),4SB)M<MO7&[#
M?V>7<4%RVI8X4JRM*FGH5S9#&X$9*$"'!SR<XB:_)X-\CY[A#1B?M0M>SI04
MI<WR:(?W6/<3:P6ET(E(4"=X`&Q0W``#IK01\<Y?8`,L]S\RV8W`.%*4Z=A%
M.I4OS(7O#I&FO<L?<8_)QR5B.94=P6YC8ZHCG(#R8&M-[]BIPL5NA-+P:EAB
M74I$E</6#N&EHPA3&61^46:&4`540`I@+!V'F>YNW]W'MUI)=-I[S6X4-0,L
M,*8K)/:QF/SXJZ:=5?I[AO\`H%^[]K^U]WI_SZ]2\C\*K6>8WN5#GGNP+,W3
MCYC_`)`4]JN:R<>[@#^5<,R&^<:4ZTJQ[9>5`Y/C]BOV6.CES"'4B9SF]`'7
MF?U)VUUQM<>[Q,<ZYAD!H!4@--<NZAQ6RL'MC<6N(`(5F_"3DC!<J^-.+\PQ
M3INI*3$&UB[O'IJ%,M"7V$11C[5%N2%`HHC]23%=(!`.]NLF<.A@UU_%]X9O
M.RQ7P<'2.'O`'+Q_%1IXW,F=4$-.55+771!P.2P)JJ)HB:(N#&`H"(B```;C
MO]P:9"IR1:R?FKR=)\CL]\<O'QBE?ZQ8Y&WQ-BO*4>H95.-GK*F,76F<CV`)
M4AKU8<OI9R!NB2"J9C;#Z>+_`%#O?[IN5KL=O^HT/:3IQIJ[:+:V31%&Z9QH
M:$+8ZQY3HK'=%IM!@DP2A:55H&J19"D[`!C7XQM%-A[0Z`)TFH&'[1$=>N;?
M9LL+**S9\,;`/;^)6MD<7O+SF2H>\X/'_BSG<PQY'9.M5YJZ6-I*=DH=6E.H
MAJH[4L#=BU>)R`RT3*$.5(D>04^P"&#<=]]]:3?^.6W(FPFX):8I*^CUA9()
MW6SM35-V%AT(*$B(-LJLJWAHJ/B6ZRPD%=5&.9HLT55A(4A!6.FB`FV``[OL
M#6^$$;6@9@`#QH*?>L-:FO>JIN07AHXIY]S&?-JCB[8TL\D^8R]DC,>.(-A7
M;'.LGJ+TTX]BY&$DB,Y&0,B`.C-3(D<&W4,7W!,8>(W#Z?[)?[FS=`PP3AX.
MF,>Z2/S4Z'JIC+Z6.)T`Q:X$>@JVA%`J*221=]DB)I@(_:"90*`[?B`:[1D?
ME0-M6Y-`^Y0^\J/7(OBE@7E95"T_.>/8NZ1[515>&D%/?C['7'2X;*N:]8X]
M1O*19U>G>1-3VE>T/<(;;4'=-FV[>V>5>Q:B!F1_QQ5S7%IJ,U">N^+J5QHV
M3A,*\ZN96+J6@;M94QO=H&SQ,:U`VX,XH9V!5.P0('0H$#I^.N9AX4^R;Y%I
MN5Y%!7X172.X+(;BGQBH4CL"\+(C"%Y<9-?Y\Y+YCN[V)<0KYUEK*TA.UYPQ
M<&*H)"4UDTC:ZF=!8O>B?V1.B81$@AN.^\VG8(MKF,C[B6:1U,9#E3L\:XJQ
M\PEQ:*`*8\E&,9AD\C9-FVD(]^U78OF#UNB\9/6;I,R+EH\:."*(.6SA$XE.
MF<IB&*.PAK?21-G:Z&85A(IXHUQ;@%5W)>)S#E9N<U?N-F6,\<2YZQK"YFX[
M"=T*RIL@L(F$!4J$XRE(Q)(ACCV)$$J*8#VD*4.FN*?P:PMKEUWMTLL#W9AN
M(KV]%D%P`-+FU7IV7Q>RN4V0U[/7.+E]ENCJF#ZC2%;96Z?`S*0;;M9A.M5]
M!9^W/MU*8>H?</75\W#!=MT;C=S30]GV)5//+#YC!2O13VP3QXP[QJHK+'.%
M*/%4>JM3_,K-8\BBKV6D#)E34E9V5='6DIF45(0`,LX54.!0[0V*``'1[7M-
MELUK\I8-+8Z9]3XE8G.+R7NS)JOE\FN/E4Y2X1NN"KM+3T)6;RWCF\E*5E9H
MWFV@1<PPF6YF2K]H^:%$[F/*4_>D<!((AT'KJS=]IBWG;76$IHQW56Q/##4J
MOZC^(Z*QE6F5-QUS6YIT>IQJCI6.K=7R9$PT(Q4>KG=.SM(YE7$FR`N72IE#
M]I0[CF$1ZB.N6MN"BSM6V5G?3QQMRI@?1CFICKDN&(%:*4?'CAO*8$O+NZ2'
M*3D[FHCJ"=0:=7S#D!&QU9F=VX;.#3"$8A&,MY9$K7VDE#&$"$4/L&X[AN]F
MV*7:YM4MY=7!['_"?'/QS6!TA<T@J;0@&P%#[!W_`!UT3BTD-K[U5@<*A5Y\
MHO'!B/E9G/%.>KQ;K_"6?$B4"A!Q=:=0J$)(IUZU?FYF,HF^AWSPYU)`?;.*
M2R>Z/38!ZZY3>>)6N\;G%N4II)$:A2HKET`.G,BBL.`-OY?R^_76L;I:&]@4
M?K5<ZJ7`9E%&+EQQ<I?,+#4OA*_3-EK]<EYFO3BTG5%F"$PFZKD@619II*2+
M*0:>RJJ790#)"(E]-AUH^0[/!O\`MC]LN<(R01WD*^.1S']R[Y@##->X\89Q
MUA.IR$Q*US&U<;5F(D9]5LM,/&;5594B\BJS;M&QW)S+#N)$R%VVZ:V&W64>
MW6,5C%C'&V@21YD>7G,K,.IJL5?61?'5B3)?,:B<TYJUWUID2@_E@T77(]Y#
MEI[D]3;R#:/,\;KQ"\H(*DD#BJ!').X0#;;KKD[WB=I>;ZW?7']=H'3L4@7#
MA;?*_P`E:JP(0^`2]VXB40#?;<=P_3KJG.:,#2IZ+`,%`_DWXX>+?*N;;W6_
MU"3K>3F0-Q993QM,.:9>R*LR]K)9Y*,"*-I95D`![)W2*JJ10[2'*&P!RFZ\
M0V?>)#/*U\=X,6R-P<T]H\<EE$Y;WCL6(8SQPY.B4"0K7R-\W"U1)(&Z4.:X
MU=603:@':#<ED<UU>5*4$OA`0V,'KOJ*SB4[&:6[E=>72FEV7XJ[YEN>C'[=
MRF3QUXY5SC=6YBM5V]9<OQ)Z6-/2<ME[(<QD&8-*JI%2=+L7,IVI1:+P2@=5
M)N0B9S@!A#<-]=#MFW-VR$6_FR2N&/O>Q8WR^8,!18*Y*^/JB\D;ZSRF[S+R
M*Q9D"-B6\)&2N*LJ2U=B6,<U.=8B2%:.DYB4#JN#^XJ=(J1EC]3B;IMJ-VXS
M'O%Q\P9YH)AU9U\?"F'B4:\LR6'4O'#FHK485;R7\TG%?4(9%1E];J:<B9J<
MO89#Z^,0:2*($';O`>[4!O#[T,-N=SN70GH[/T8K*V:GOD`N'V[%F7B_XX.-
M?%6T/LC5"(LEVRW*$>$DLM91GE[C=UAD0_WD=F\<I(-(M20]%E$$2K*D^$ZA
MB]-;39.*;?L4ANFN=+=G`O=G3H/0K9KR6<:"/=4]>W]>NC\P]H4/RAWKKURJ
M->OM5L5*MD4UFZQ:X23KU@B'J8*M9*'F&BK&19K$'^PNV6,&X;"4=A#80`=1
MKZS9?0&UE_9=6OI68&AJM5*H6;*?@[Y93%,M["P7GA?F>6%Y#S+9-1RJDS;G
M*DRFX\>C8M_I+-0&THQW(:38D*H3J"8E\5CDN_IIO4CI=3]CN#1HS#17.@K1
M;:@O+4%N,C?M]ZVD<991H>8:7!9#QK:X:YTRR-"/8>?@G17;)PB<I3"BL)?W
MC-^V,/8NW6`BR*@"4Y2F`0U[597UON%I'>VK@8G"IH<J]V:U;V.8=+A0K(.X
M>OZ]3`]I-`K#ABFX?RWT+FC,A!CDO'O+]_K^`_JT#FDT!"NTN59'D4\DN,N$
MU(>Q4>^B[CGR?C5B4G'+=R1=2*5<$%-"U74B!C*Q-?8G4*H1(X%</S[)I!VB
M90G&\LY=:\=MBZ(B6]>-+8QB<32II7U%2+:$RFO\M5#KQ#\(<A,;!9N>W*-.
M0?YOS`:4DJ3'V),0FH&#M!A7E[G+-%@`\;-6IN8&[)L`%^2B@`NP>]VDYW@7
M&+N&XEY#O/OW%SBQKJ'0.G4],EDNI`UWELQ:%?Z4-@`/]/Z1WUZJ!04K50<\
M\U!;E5S%=<=,HX#Q:SIT+.N\Z+7Q)O8[)9)F!@JO^1XAI+*?/HUVGW.:?C)D
M<BFG[+;8AP#N$"B)@YG=]_&V[A%9::ND%0LK(GR?"*KT..O-S^.6:;UA1]16
M4$_I=:C[,WN<-:'KZMV4CYW\HI%Q$/=*ICZ[.'D>("==PWC74>0NP"X`X@75
MFW<A-[NAL"W$"J&)XS'WJ?(CL`CMOL'I]^NJ-.N2Q*+=AY)?0N7>.N*_Y2.X
M-?<-W#+?YS^JD3)&!4YYG"#!&AODSG=&?"\]P%P7("?;MV#OOK1R;P&;W'LX
M:2YX)KV`-<?OHL@B>8S*!^F.JE(4=P`=;Q8U$_DURFC>/4CAVG,JC(7[)F?;
M[_#O%]3;232O1;N82:`^D']CL[]%TV@X:+9G*=0Q47#A41[4TC#OMHMUWN+;
MC#&P:YI9-`&6-"<\E>QFNO@L99UY;Y/XK5".REGG$52'%(V*NUVUV'&61GUB
MGZ6:S22$3'RSFM66EU0+!%I/W)"K@S=`Y(4>XJ1@`=67^[3;:V.2ZC`9(<34
M&F5,B<^[L5WE')N*GHS<IO&Z+E(W>DNDDND<`$H'263(HF;8P%,`F(8!Z@&V
M^MW!*V>%LS/A<*K&01@5C_)$IE&)8-7&,JM3+4Z`[D\HVN-OE:>@V:(MQ41.
MQ=1=6M1WCA9<.TQ5$T2D+U[A]-1[Z>>W@=/;MUN:*D5IECUH@%<%%SA_R?R[
MRKH55RW_``FHU&QO8Y.V1BIC9,EI^WLE*I,RE>65)#%H49%.4WDM&&[=WQ#%
M0,!A#N^'6HV7=[G>+=MV&:8W$]<J$@YGN[%4@MP.:G87<0`1]1`-=&,E:J],
M_<Y5L,<EJIQP;4J">O+/B-[E?\YV:S6.)AVB#*QO*^,`$95*#>9A=\L+7W2K
M"FFCL(E$0$`WY:_Y%\INXVP-JXMK]CDLX@U-U"BEEAJ]SV1Z<A;)R/K+!.1=
M./I`U68L,RP>1R!P;_,JJV>HTJ5:NOFR*D,D9GV@4I3`<0-K<V,SKANI]*K"
M5E@XB!=P]=P`.F_J(!_RZV)(`J<E108J7+2TYNR=F/'/'G&<798_`]M_(&0L
MA9$N*]*KI[RFW%R\KU4B(FNVFP3A8U+8%W:R;-OW"`)^YOOKF8=[?N%U);;<
MP/\`)=1[C[M#T&-":]RR/B='36*5"EI1)"]2,*"N0Z_7:U82.7"1X^K6-[:H
MD[1,_:U=I2K^!K;D%').IDC-OW8AMWFUT$)E<VLHH[QJL:[H([:RD]!\715"
MA%>N;%0QKRP8\9KI#N8ED_PJ;+J&0$OJTNF9<MJ/7`K`UN#@I)ZF8R*)W'SA
MU2I!V]G;W"&_,_[BAAW<;3<BCS&75H33I3`%9&Q/>TN:*M"]K%?,^IY@Y37_
M`(YTZ%<O(RB8CK.3U;ZM]4C2R#FP3RL*I7"UR:A8M^A\BF":WS7>=-7O[0*`
M@(ZML>20WN\R[5$-4;&@A]'#$YBA`R\%:6.`J1@IJ!KIVY*Q-7(FJ'`(HJ<O
MN2H<5<4QV3SU(]U*^R/CG'WT9.6)""B:_6=G7`E1>G9/P,6,%W[HI>W^]V[>
MXOKK0;WN[MJM8I=&I\CVMKV:NJO#2<:*4Y!-L'<.X].H!MON'W==NNMS%(9(
MF/\`S#%6D46-<U9&+B#$.3<JGBC3A,<46TW8\,1T5B>5)689Y+FCRO#(N"M!
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M`S,Z509,Q?NQ$#+KG*DD0HF$>@`,/>]S&U6?S)%3JHKHXW2'2T5*_6M6SDQ*
M.X![8L18NK<+(.&XSC!++TS,VFMQZVQE3F2;8X;P4O)-$S;'02=$2,?H580^
M+5+6XO;AK))6!K'-!S%?57V*TBAQ4A/>#[P].[U+_1Z_R^_6SHS[!4Q7LZS*
MBQ!F_!&*^16.YO%N7ZA&W"G3J0>\Q>E$CJ/?)E.#29A)!/9W#S3`QQ,@Y0,1
M0@[AN)1,4==N.UV6ZP&VO&!T1%*]1X=ZR1320N#HU01_AA\^."EGM&0?'UGN
M-N-+.LI)J89O)Q:2EA:D[E31S^+D4ST2R2B")?:2>`O#O50Z%,4PZ\M'".1\
M9FEO^+W`F#C40R.+<.P5!;ED#2JG.O(YV%DK:./5<5[SQY,Q<N>K<M.&MUJ-
MJC%#,Y-W6EI*M;N&PBDY,-;O4:E[9A4(/^KD5$]_V1VVU?!]2;VP'D[]92B5
MIH=+32OC_@L8MA(=+"*]^2[J_P#\Q7QW!J;Z#@?,LO)@3=)BZD*/'H**=`!,
M[IK,2JY0$P^I4##^&LDGU6LGC3;6$[Y/#`*X;?C[[VM"PM,>17RC\V3+5'A_
MQHD\/UJ4.=JMD%Q'O'K]HS<`"?S!K_<F4)3X44RG[N]HV7=%VW((#MJ!/ROE
M>]@6^UV8AC=\1J0>[H:+*RVLH,97DGI3'QJI:<)O#9`XRMZ&?>75K2S_`)T<
M21+"E%R*SV;I5=GA$%PEI-W.`:1OEB;+"`IKNR$:(*%[DTC"!3AT''.!-LKO
M^[;N\S7CA\).IH]?>K;B]!;Y4(HSMR*O4(0"!T``W^[[@]`#[@`->DL:&-T@
M`#L"UE*=Z\]7(H_9;XU8US3;L>WVW$M3&Z8J-8C4&TTZYV*F35?"ULT8Z?*B
M\K[YD=8DDP;E2."G<'8)@#U'6IO-EL[Z=MU/J,[/A/8KHWO:36E%\RE<3\.T
MK)R.:B1UEMF6FE?7JD=D'(EWME^LL-679S*/(2#=V:5?H0S%X<XBJ#9),5-Q
M`PCN.L=OL5G;7GSD=?-HJF1Q4DQZ@(?AK</!+2!G16+$DCA''DMF>LY^?PRB
MV4*C29O'<%/!(OR(-*G89!"5E8\T41<L<NHX?-B&!8Z9E2`&P&`!VU$-C"=P
M^?(_5#*`^NOXJ_S'!GECX"LN:FJQ8ER[@[%^=(..K^3JHTL;2$FFEDKSWYA]
M&3U7LC#?Y&PU:PQ+EE-5Z::"8>QPT72.)=RB(E$0UK[O;+2]T^<#J8ZH/8>U
M7!Q&2Q7,\-\0W!6!+DMSD3+L369EA88.L93R3;;E4FD[$G]V)EG%:D)`(F8>
MQJOQ(G?)N?;-\0=>NH,FPV\L@?*Y[@.A-1Z%<)",E*I,@)AV@`%#IL!0V```
M````/L``#6[C;H8&`4:T4"L))S7BX2]Y%5+I^\(9,=]]NTX=I@Z=>I1U5[`]
MCF')PHC30XY+%>%L*X_X_P!!B\88OAU(*E0SR:?QT8M(/I55%U89=[.RIQ>R
M2[EVH5Q)2"B@`8VQ`'M#H``$6PL8;"W$$(H`3]YJJN=J-5EH-2Q6F.:M4;,@
M\5L6Y)RK$9MES7:!RC`TUQCZ,M]&R#;*7))T]U*+3+B$6"O23)!PV6DEA5,)
MRF,([==B@&M/<;%97-S\Z_5\S2E0>BOUNI3HLI4''C/'K)ZQ862]V1-^Z([5
M<WVZS]V?H'(D"((LGL^[>.&C02AN*1#`03_%MN(B,NULF60TPDD'.N:M)JN_
MG#N*(;`.^W0>@;;AOZ?AJ8XO`K'35W_?]RH:],U&N:XH8CD;W8,G0;*T8ZO]
MN^7_`#A:<6W>SX^>6\S-,$FCBU,J](M8>P/4$@[2N7+91R!>GN;=-:;^Q6GS
M,UPPN892"=.&(61\A>1V`+,='I3&B1!X=A*VF:24=KOE7]PM<Y<)E9PY[/=[
MY6?=O'9&X>V'8B0Q44^O:4-QUM((!`*`D^*L*[D(;ZS$8UZA46(!P=CT<V%Y
M"_2%?XJDQZ.+0L'U)_\`+_DD\X6Q&BAB`7"-%7ZJ4%/?%/WNFVX!TU`.V6AO
MAN-/]2&EM>Y7AY#"P9%?I'X1QY%YHL'(!E#*(Y1M-'B,<S<]]1?J(NZC!2:T
MO&QI8LZXQS=1%^N)Q6(F"I@Z"80U1FW0-O3?AH%PX`&G8,D#SHT'M67-;'+)
M6)HB:%%B#-6#L=<@*@VHF4(12>K#2S5FX(L$9)_%'+8*A+(3<"[%U'+-W!B-
M9!N4YDQ-V*`':8!`=0KNP@O8F17`J&.#AXC)9&OT@]XHLN$`P%`#;=WVB'IJ
M6QNAH:,@L:ZO>Z77\CTNUX_MC,TC5[K7I>KV)@1PNS.]A9QBO'2;0CML=-RV
M,X9N#E!1,Q3D$=P$!#?6&ZMH[R!UM-^R\4=WCL50:&HS6`;YPOXYY,PI3^/]
MWQRQG<<4"#C*_2FCB0DTK!5F$1&DB&8P=N;.D;(P=&C$_EUU2.`,Z2$Q5>\!
M$-:>[XWMEY8_(31AT#!1F-*"M5?YCNU2#IE3AJ'5*W2:VU%C6ZA`0]9K[$RZ
MSH[.&@F"$9&M3N7)E'#@S=DV(3O.8QS[;B(B.MO:VT-G"VWMV!D+&@#'L_@K
M"2<U\C)>,*#F&GRU`R;4H2[4Z<233DX">:@Z9.!15*NV7)U*LU>-%R%4171,
MFLBH4#$.4P`.K+VQ@W"'Y>Y%8O:JQO<Q^H88+&%7XSU"HJ0Y8F[9L&*K[AFX
MB*Y)9IR'+0+8K`Y3M&BK1_-K+/XY+L`HMW*JR)D_A,40Z:C0;3%;4\MSB!D"
M<%0DDDGM4A/9_`OIMZ!^KTUL??[`J+V-9$31$T11$Y<_\%#_`."KKB^39N_R
M_@5)@S556&?^/(O_`*Z?^V+KG+/]W_+[5=/D/$J^^"_]AB/_`";3_9:[_:OV
M/MVE179+[J?[/]'_`&2ZW3D*_35JHFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
BHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
